[go: up one dir, main page]

US20050131032A1 - (Oxime)carbamoyl fatty acid amide hydrolase inhibitors - Google Patents

(Oxime)carbamoyl fatty acid amide hydrolase inhibitors Download PDF

Info

Publication number
US20050131032A1
US20050131032A1 US11/039,516 US3951605A US2005131032A1 US 20050131032 A1 US20050131032 A1 US 20050131032A1 US 3951605 A US3951605 A US 3951605A US 2005131032 A1 US2005131032 A1 US 2005131032A1
Authority
US
United States
Prior art keywords
compound
phenyl
oxime
scheme
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/039,516
Inventor
Sing-Yuen Sit
Kai Xie
Hongfeng Deng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/039,516 priority Critical patent/US20050131032A1/en
Publication of US20050131032A1 publication Critical patent/US20050131032A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/48—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/60—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups having oxygen atoms of carbamate groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel (oxime)carbamoyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase and are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase.
  • cannabinoids The analgesic properties of cannabinoids have been known for many years and to many cultures. Cannabinoids are active in many pre-clinical models of pain, including neuropathic pain. Within the last few years, several endogenous cannabinoids, including the fatty acid amides arachidonylethanolamide (anandamide), and arachidonyl amino acids such as N-arachidonylglycine, homo- ⁇ -linolenyl-ethanolamide and docosatetraenyl-ethanolamide, as well as 2-arachidonyl-glycerol, have been shown to induce analgesia in laboratory animals (DeVane, W. A. et.
  • arachidonyl amino acids such as N-arachidonylglycine, homo- ⁇ -linolenyl-ethanolamide and docosatetraenyl-ethanolamide, as well as 2-arachidonyl-glycerol
  • FAAH fatty acid amide hydrolase
  • a seventh aspect of the present invention a method of treating a condition or disorder by inhibiting fatty acid amidohydrolase in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a method of treating neuropathic pain in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a ninth aspect of the present invention a method of treating acute pain in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a method of treating chronic pain in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • an eleventh aspect of the present invention a method of treating emesis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a method of treating anxiety in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a method of altering feeding behaviors in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a fourteenth aspect of the present invention a method of treating movement disorders in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a method treating glaucoma in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a method of treating brain injury in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a method of treating cardiovascular disease in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • a pharmaceutical composition for treating a condition or disorder requiring inhibition of a fatty acid amidohydrolase comprising a therapeutically effective amount of a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or diluent.
  • the present invention provides a novel series of compounds of Formula I, its hydrates and solvates thereof: or a pharmaceutically acceptable salt or solvate thereof, wherein
  • A is represented by Formula II: wherein a is 1, R is C 1-12 alkoxy; phenoxy; pyridyloxy; or amido optionally substituted with C 1-16 alkyl; and R 1 is a bond.
  • R 2 is preferably hydrogen or methyl, and R 3 is preferably methyl, or phenyl optionally substituted with one or more halo, haloalkyl or nitro.
  • B is represented by Formula IV:
  • X is preferably CH, R 4 is preferably halo, and b is 1.
  • X is nitrogen, however, b is preferably 0.
  • An embodiment or aspect which depends from another embodiment or aspect will describe only the variables having values and provisos that differ from the embodiment or aspect from which it depends. For example, if a dependnent embodiment describes a variable as being “phenyl or pyridyl”, wherein said phenyl and pyridyl were described in the independent embodiment as being “optionally substituted”, then the phenyl and pyridyl of the dependent embodiment will also be optionally substituted.
  • the present invention may include any and all possible stereoisomers, geometric isomers, diastereoisomers, enantiomers, anomers and optical isomers, unless a particular description specifies otherwise. More particularly, the groups attached to the oxime portion of compounds of Formula (I), i.e., N ⁇ C, may assume transoid or cisoid configurations.
  • halo or “halogen” includes fluoro, chloro, bromo and iodo.
  • alkyl or “alkylene” includes straight or branched chain configurations.
  • the compounds of this invention can exist in the form of pharmaceutically acceptable salts.
  • Such salts include addition salts with inorganic acids such as, for example, hydrochloric acid and sulfuric acid, and with organic acids such as, for example, acetic acid, citric acid, methanesulfonic acid, toluenesulfonic acid, tartaric acid and maleic acid.
  • the acidic group can exist in the form of alkali metal salts such as, for example, a potassium salt and a sodium salt; alkaline earth metal salts such as, for example, a magnesium salt and a calcium salt; and salts with organic bases such as a triethylammonium salt and an arginine salt.
  • the compounds of the present invention may be hydrated or non-hydrated.
  • the compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions.
  • the compounds of this invention may also be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, all using dosage forms well known to those skilled in the pharmaceutical arts.
  • the compounds can be administered alone, but generally will be administered with a pharmaceutical carrier selected upon the basis of the chosen route of administration and standard pharmaceutical practice.
  • Compounds of this invention can also be administered in intranasal form by topical use of suitable intranasal vehicles, or by transdermal routes, using transdermal skin patches. When compounds of this invention are administered transdermally the dosage will be continuous throughout the dosage regimen.
  • the dosage and dosage regimen and scheduling of a compounds of the present invention must in each case be carefully adjusted, utilizing sound professional judgment and considering the age, weight and condition of the recipient, the route of administration and the nature and extent of the disease condition. In accordance with good clinical practice, it is preferred to administer the instant compounds at a concentration level that will produce effective beneficial effects without causing any harmful or untoward side effects.
  • Scheme 1A Reaction conditions: (i) R-halide, NaH, DMF, room temp.; (ii) NaOH, EtOH, room temp., (iii) (a) N 3 P(O)(OPh) 2 , Et 3 N, toluene at room temp. following by 90 min. at reflux, (b) addition of oxime C at room temp. with stirring for 1 hr., heating to 85° C.; n is 0 to 3; R, and R 2 are as defined above.
  • 2,4-Difluoro-benzaldehyde oxime (Scheme 1, Compound C) To a mixture of 2,4-difluorobenzaldehyde (0.80 g, 5.6 mmol) and hydroxyamine HCl salt (0.43 g, 6.2 mmol) in EtOH (5 mL) was added K 2 CO 3 (0.85 g, 6.2 mmol). The resultant mixture was stirred at rt for 24 hours. The mixture was diluted with MeOH (20 mL). The precipitates were filter off and washed with MeOH. The product from filtrate was purified by recrystalization (EtOAc/Hexanes). This compound was obtained as a white solid (0.84 g, 5.3 mmol, 94% yield).
  • reaction mixture was stirred at r.t. for 10 min. and then at 80° C. for 1 h.
  • the mixture was diluted with EtOAc, washed with H 2 O. After filtration and concentration in vacuo, the residue was purified by by preparative HPLC (YMC 30 ⁇ 100 mm (5 uM packing), 10% MeOH/90% water/01% TFA as mobile phase A, 90% MeOH/10% water/0.1% TFA as mobile phase B).
  • H4-FAAH cells Homogenates of crude membranes were prepared from H4 cells that express transfected human FAAH (H4-FAAH cells). Briefly, cells were grown in DMEM supplemented with 10% FBS and Geneticin at a final concentration of 500 ⁇ g/ml(Gibco BRL, Rockville, Md.). Confluent cultures of H4-FAAH cells were rinsed twice with phosphate-buffered saline [138 mM NaCl, 4.1 mM KCl, 5.1 mM Na 2 PO 4 , 1.5 mM KH 2 PO 4 (pH 7.5), 37° C.] and incubated for 5 to 10 minutes at 4° C. in lysis buffer [1 mM sodium bicarbonate].
  • Example 5 (40 mg/kg, i.p.) suppressed the development of thermal hyperalgesia induced by paw carrageenan. Paw carrageenan injection ( ⁇ , 0.45 Carr) produced strong thermal hyperalgesia as evidenced by the short escape latencies seen in vehicle treated rats ( ⁇ ,2:15 hr, Carr) as compared to the long baseline latencies (0:00 hr). Animals pretreated with Example 5 (#1, 0:15 hr) failed to exhibit hyperalgesic responses (compare ⁇ to ⁇ at 2:15 hr) and instead the latencies for drug treated animals were comparable to baseline.
  • PAW EDEMA MODEL Inflammation-induced Edema
  • Example 5 The effects of Example 5 on carrageenan-induced edema were examined in a quantitative manner (plethysmometry). Injections of carrageenan (2% lambda) into the plantar aspect of both hind paws, resulted in an increase in combined total paw volume (swelling) measured 3 hours post-injection.
  • Example 5 inhibited swelling by 26% at 40 mg/kg (Ex. 5-40, ip administered at ⁇ 30 min and +2hr relative to carrageenan) but showed no efficacy at 20 mg/kg (Ex. 5-20, ip).
  • the reference agent dexamethasone (Dex, 1 mg/kg, ip) inhibited swelling by 70%. Table IV, below, summarizes the data.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This non-provisional application claims priority from provisional application U.S. Ser. No. 60/355,302 filed Feb. 8, 2002.
    • FIELD OF THE INVENTION
  • The present invention relates to novel (oxime)carbamoyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase and are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase.
    • BACKGROUND OF THE INVENTION
  • Effective treatment of pain with current therapies is limited by adverse effects and a lack of efficacy against all components of pain.
  • Current research is aimed at understanding the molecular and physiological components of pain processing to develop more effective analgesics (Levine, J. D., New Directions in Pain Research: Meeting Report Molecules to Maladies, Neuron 20: 649-654, 1998; Pasternak, G. W., The Central Questions in Pain Perception May Be Peripheral, PNAS 95:10354-10355, 1998).
  • The analgesic properties of cannabinoids have been known for many years and to many cultures. Cannabinoids are active in many pre-clinical models of pain, including neuropathic pain. Within the last few years, several endogenous cannabinoids, including the fatty acid amides arachidonylethanolamide (anandamide), and arachidonyl amino acids such as N-arachidonylglycine, homo-γ-linolenyl-ethanolamide and docosatetraenyl-ethanolamide, as well as 2-arachidonyl-glycerol, have been shown to induce analgesia in laboratory animals (DeVane, W. A. et. al., Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptors, Science 258:1946-1949, 1992; Hanus, L. et. al., Two New Unsaturated Fatty Acid Ethanolamides in Brain that Bind to the Cannabinoid Receptor, J. Med. Chem. 36: 3032-3034, 1993; Machoulam, R. et. al., Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds To Cannabinoid Receptors, Biochem. Pharmacol. 50: 83-90, 1995; Vogel, Z. et. al., Cannabinomimetic Behavioral Effects of and Adenylate Cyclase Inhibition By Two New Endogenous Anandamides, Eur. J. Pharmacol. 287: 145-152, 1995; Hargreaves, K. M. et al., Cannabinoids Reduce Hyperalgesia and Inflammation Via Interaction With Peripheral CB1 Receptors, Pain 75: 111-119, 1998; Rice, A. S. C., et. al., The Anti-Hyperalgesic Actions of the Cannabinoid Anandamide and the Putative CB2 Receptor Agonist Palmitoylethanolamide in Visceral and Somatic Inflammatory Pain, Pain 76:189-199, 1998; Huang, S. M., et al., Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain, J. Bioloaical Chemistry, 276: 46, 42639-42644, 2001). The ability of cannabinoid receptor antagonists and cannabinoid receptor antisense to induce hyperalgesia in animals suggests that endogenous cannabinoids regulate the nociceptive threshold (Hargreaves, K. M. et al., Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia, J. Neurosci. 18: 451-457, 1998; Piomelli, D. et. al., Control of Pain Initiation By Endogenous Cannabinoids, Nature 394: 277-281,1998; Fields, H. L. et. al., An Analgesia Circuit Activated By Cannabinoids, Nature 395: 381-383, 1998). Elevation of levels of neuroactive fatty acid amides such as anandamide may provide a unique mechanism to achieve analgesia. The mechanisms by which endogenous cannabinoids are synthesized are not well understood; therefore, targets for drugs aimed at increasing the synthesis of these compounds are slow to be identified.
  • Anandamide and the other identified endogenous cannabinoids are inactivated through a cleavage mechanism by a membrane-bound enzyme, fatty acid amide hydrolase (FAAH). FAAH, therefore, provides an important target for regulating the activity of endogenous cannabinoids. The inhibition of FAAH may elevate levels of anandamide or other endogenous cannabinoids to increase the nociceptive threshold. Furthermore, the inhibition of FAAH would also extend the therapeutic benefits of other cannabinoid agonists in the treatment of emesis, anxiety, feeding behaviors, movement disorders, glaucoma, neuroprotection and cardiovascular disease.
    • SUMMARY OF THE INVENTION
  • The above and other objects and advantages, which will be apparent to one of skill in the art, are achieved in the present invention which is directed to, in a first aspect, a compound of Formula I:
    Figure US20050131032A1-20050616-C00001
    or a pharmaceutically acceptable salt or solvate thereof, wherein
    • A is dibenzofuranyl, dibenzothienyl, naphthyl, indolyl, fluorenyl, carbazolyl, or represented by Formula II:
      Figure US20050131032A1-20050616-C00002
      wherein
    • a is 1 or 2,
    • R is C1-16 alkoxy optionally substituted with phenyl, pyridyl or morpholinyl;
    • phenyl optionally substituted with C1-4 alkyl; phenoxy; phenyl-C1-4 alkyloxy-; pyridyloxy; pyridyl-C1-4 alkyloxy-; —N(H)—C(O)—C1-16 alkyl; or —C(O)—N(H)—C1-16 alkyl;
    • R1 is a bond or a C1-3 branched or linear aliphatic hydrocarbon; and
    • B is C1-4 alkyl, indolyl, benzofuranyl, benzothienyl, dibenzofuranyl, dibenzohienyl, fluorenyl, carbazolyl, naphthyl, quinolinyl or isoquinolinyl, wherein each is optionally substituted with one or more of the same or different substituent selected from the group consisting of C1-4 branched or linear aliphatic hydrocarbon, C1-4 alkoxy, halo, haloalkyl, nitro and (C1-3 alkyl)0-2 amino-; or represented by Formula III, or Formula IV:
      Figure US20050131032A1-20050616-C00003
      wherein
    • R2 is hydrogen, halo or C1-4 alkyl;
    • R3 is C1-4 alkyl, pyridyl, or phenyl optionally substituted with one or more of the same or different substituents selected from the group consisting of halo, C1-4 haloalkyl and nitro;
    • X is CH or nitrogen;
    • R4 is C1-4 branched or linear aliphatic hydrocarbon, C1-4 alkoxy, halo, haloalkyl, nitro or amino; and
    • b is 0 to 3,
    • provided that if R2 is halo, then R3 is not halo; and if R3 is halo, the R2 is not halo.
  • According to another embodiment of the first aspect of the present invention are provided compounds of Formula I according to the first embodiment of the first aspect wherein A is dibenzofuranyl.
  • According to another embodiment of the first aspect of the present invention are provided compounds of Formula I according to the first embodiment of the first aspect wherein A is indolyl.
  • According to another embodiment of the first aspect of the present invention are provided compounds of Formula I according to the first embodiment of the first aspect wherein A is represented by Formula II:
    Figure US20050131032A1-20050616-C00004
    wherein
    • a is 1,
    • R is C1-4 alkoxy optionally substituted with phenyl, phenoxy, pyridyloxy, or amido optionally substituted with C1-16 alkyl,
    • R1 is a bond; and
    • B is represented by Formula III:
      Figure US20050131032A1-20050616-C00005
      wherein
    • R2 is hydrogen, and
    • R3 is methyl, pyridyl, phenyl optionally substituted with one or more halo, haloalkyl or nitro.
  • According to another embodiment of the first aspect of the present invention are provided compounds of Formula I according to the first embodiment of the first aspect wherein B is represented by Formula III:
    Figure US20050131032A1-20050616-C00006
    wherein
    • R2 is hydrogen or methyl; and
    • R3 is methyl or phenyl optionally substituted with one or more halo, haloalkyl or nitro.
  • According to another embodiment of the first aspect of the present invention are provided compounds of Formula I according to the first embodiment of the first aspect wherein B is represented by Formula III:
    Figure US20050131032A1-20050616-C00007
    wherein R2 is hydrogen or methyl; and R3 is methyl, or phenyl optionally substituted with one or more halo, haloalkyl or nitro.
  • According to another embodiment of the first aspect of the present invention are provided compounds of Formula I according to the first embodiment of the first aspect wherein B is represented by Formula IV:
    Figure US20050131032A1-20050616-C00008
    wherein X is CH; R4 is halo; and b is 1.
  • According to another embodiment of the first aspect of the present invention are provided compounds of Formula I according to the first embodiment of the first aspect wherein B is represented by Formula IV:
    Figure US20050131032A1-20050616-C00009
    wherein X is nitrogen; and b is 0.
  • According to another embodiment of the first aspect of the present invention are provided compounds of Formula I according to the first embodiment of the first aspect wherein B is represented by Formula V:
    Figure US20050131032A1-20050616-C00010
    wherein X is nitrogen.
  • According to various embodiments of a second aspect of the present invention are provided compounds of Formula III, Formula IV or Formula V:
    Figure US20050131032A1-20050616-C00011
    wherein
    • R2 is hydrogen, or methyl,
    • R3 is C1-4 alkyl, pyridyl, or phenyl optionally substituted with one or more halo, haloalkyl or nitro,
    • X is CH or nitrogen,
    • R4 is C1-4 branched or linear aliphatic hydrocarbon, C1-4 alkoxy, halo, haloalkyl or amino, and
    • b is 0 to 3.
  • According to various embodiments of a second aspect of the present invention are provided compounds of Formula VI:
    Figure US20050131032A1-20050616-C00012
    or a pharmaceutically acceptable salt or solvate thereof, wherein
    • a is 1;
    • R is C1-12 alkoxy;
    • R2 is hydrogen or methyl; and
    • R3 is methyl, pyridyl, phenyl optionally substituted with one or more halo, haloalkyl or nitro.
  • According to another embodiment of the second aspect of the present invention are provided compounds of Formula VI according to the first embodiment of the second aspect wherein R2 is hydrogen and R3 is phenyl optionally substituted with one or more halo, haloalkyl or nitro.
  • According to another embodiment of the second aspect of the present invention are provided compounds of Formula VI according to the first embodiment of the second aspect wherein R2 is methyl and R3 is methyl. According to another embodiment of the second aspect of the present invention are provided compounds of Formula VI according to the first embodiment of the second aspect, a member selected from the group consisting of
    • pyridine-3-carbaldehyde, O-[[(4-undecyloxy-phenyl)amino]carbonyl]oxime;
    • pyridine-3-carbaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-decyloxy-phenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-octyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • 3,4-difluorobenzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • 2,6-difluorobenzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • 2,4-difluorobenzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • 3-fluorobenzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • pyridine-3-carbaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-decyloxy-phenyl)amino]carbonyl]oxime;
    • pyridine-3-carbaldehyde, O-[[(4-decyloxy-phenyl)amino]carbonyl]oxime;
    • pyridine-3-carbaldehyde, O-[[(4-dodecyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-octyloxu-phenyl)amino]carbonyl]oxime;
    • 2,3-difluorobenzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-undecyloxy-phenyl)amino]carbonyl]oxime;
    • 2,4,5-trifluorobenzaldehyde, O-[[(4-nonyloxy phenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-phenoxyphenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-undecyloxy-phenyl)amino]carbonyl]oxime;
    • 4-trifluoromethyl-benzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-phenoxyphenyl)amino]carbonyl]oxime;
    • pyridine-3-carbaldehyde, O-[[(4-heptyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[[4-(2-phenylethoxy)phenyl]amino]carbonyl]oxime;
    • 2-fluoro-3-trifluoromethyl-benzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • (4-undecyloxy-phenyl)-carbamic acid phenyl ester;
    • propan-2-one, O-[[(4-heptyloxy-phenyl)amino]carbonyl]oxime;
    • propan-2-one, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[[4-(phenylmethoxy)phenyl]amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[[4-(2-phenylethoxy)phenyl]amino]carbonyl]oxime;
    • 2-fluoro-5-trifluoromethyl-benzaldehyde, O-[[(4-nonyloxy-phenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[[4-(phenylmethoxy)phenyl]amino]carbonyl]oxime;
    • 3-pyridinecarboxaldehyde, O-[[(3-phenoxyphenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[[4-(3-phenylpropoxy)phenyl]amino]carbonyl]oxime;
    • benzaldehyde, O-[[(3-phenoxyphenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-pentyloxy-phenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-butoxy-phenyl)amino]carbonyl]oxime;
    • pyridine-3-carbaldehyde, O-[[(4-heptyloxy phenyl)amino]carbonyl]oxime;
    • 3-pyridinecarboxaldehyde, O-[[(4-phenoxyphenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[[4-(3-phenylpropoxy)phenyl]amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-pentyloxy-phenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-dodecyloxy-phenyl)amino]carbonyl]oxime;
    • propan-2-one, O-[[(4-decyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-dodecyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-pentyloxy-phenyl)amino]carbonyl]oxime;
    • 2,4-difluorobenzaldehyde, benzaldehyde, O-[[(4-nonanoylamino-phenyl)amino]carbonyl]oxime;
    • 4-fluorobenzaldehyde, O-[[(4-heptyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-pentyloxy-phenyl)amino]carbonyl]oxime;
    • propan-2-one, O-[[(4-undecyloxy-phenyl)amino]carbonyl]oxime;
    • propan-2-one, O-[[(4-dodecyloxy-phenyl)amino]carbonyl]oxime;
    • pyridine-3-carbaldehyde, O-[[(4-pentyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-propoxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-heptyloxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-butoxy-phenyl)amino]carbonyl]oxime;
    • benzaldehyde, O-[[(4-hexyloxy-phenyl)amino]carbonyl]oxime;
    • propan-2-one, O-[[(4-heptyloxy-phenyl)amino]carbonyl]oxime;
    • pyridine-3-carbaldehyde, O-[[(4-hexyloxy-phenyl)amino]carbonyl]oxime; and
    • pyridine-3-carbaldehyde, O-[[(4-butoxy-phenyl)amino]carbonyl]oxime.
  • According to various embodiments of a third aspect of the present invention are provided compounds of Formula VII:
    Figure US20050131032A1-20050616-C00013
    or a pharmaceutically acceptable salt or solvate thereof,
    wherein
    • a is 1;
    • R is C1-12 alkoxy;
    • R4 is halo;
    • X is CH or nitrogen; and
    • b is 0 to 2,
    • with the proviso that when X is nitrogen then b is 0.
  • According to another embodiment of the third aspect of the present invention are provided compounds of Formula VI according to the first embodiment of the third aspect wherein X is CH and is a member selected from the group consisting of:
    • (4-undecyloxy-phenyl)-carbamic acid phenyl ester;
    • (4-decyloxy-phenyl)-carbamic acid phenyl ester;
    • (4-dodecyloxy-phenyl)-carbamic acid phenyl ester;
    • (4-octyloxy-phenyl)-carbamic acid 2-fluoro-phenyl ester;
    • (4-octyloxy-phenyl)-carbamic acid phenyl ester;
    • (4-heptyloxy-phenyl)-carbamic acid phenyl ester; and
    • (4-decyloxy-phenyl)-carbamic acid 2-fluoro-phenyl ester.
  • According to various embodiments of a fourth aspect of the present invention are provided compounds of Formula VIII
    Figure US20050131032A1-20050616-C00014
    or a pharmaceutically acceptable salt or solvate thereof,
    wherein
    • a is 1;
    • R is C1-12 alkoxy;
    • R1 is a C1-3 branched or linear aliphatic hydrocarbon;
    • R4 is phenyl, C1-3 alkoxy or halo;
    • X is CH or nitrogen; and
    • b is 2.
  • According to another embodiment of the fourth aspect of the present invention are provided compounds of Formula VIII according to the first embodiment of the fourth aspect wherein X is CH and is a member selected from the group consisting of:
    • (4-butoxy-benzyl)-carbamic acid 4-fluoro-phenyl ester;
    • pyridine-3-carbaldehyde, O-[[(4-butoxy-benzyl)amino]carbonyl]oxime;
    • (4-butoxy-benzyl)-carbamic acid phenyl ester;
    • [1-(4-butoxy-phenyl)-propyl]-carbamic acid 2-fluoro-phenyl ester;
    • (4-butoxy-benzyl)-carbamic acid 2,4-difluoro-phenyl ester;
    • (4-butoxy-benzyl)-carbamic acid 4-methoxy-phenyl ester;
    • [1-(4-butoxy-phenyl)-propyl]-carbamic acid 4-fluoro-phenyl ester;
    • (4-butoxy-benzyl)-carbamic acid 2-fluoro-phenyl ester; and
    • (4-butoxy-benzyl)-carbamic acid 3-chloro-phenyl ester.
  • According to various embodiments of a fifth aspect of the present invention are provided compounds of Formula IX:
    Figure US20050131032A1-20050616-C00015
    or a pharmaceutically acceptable salt or solvate thereof,
    wherein
    • a is 1;
    • R is C1-12 alkoxy;
    • R1 is a C1-3 branched or linear aliphatic hydrocarbon; and
    • X is CH or nitrogen.
  • According to another embodiment of the fifth aspect of the present invention are provided compounds of Formula IX according to the first embodiment of the fifth aspect wherein X is CH and is a member selected from the group consisting of:
    • (4-butoxy-benzyl)-carbamic acid quinolin-6-yl ester;
    • (4-butoxy-benzyl)-carbamic acid naphthalen-2-yl ester;
    • [1-(4-butoxy-phenyl)-propyl]-carbamic acid quinolin-6-yl ester; and
    • (4-butoxy-benzyl)-carbamic acid naphthalen-1-yl ester.
  • According to various embodiments of a sixth aspect of the present invention is provided a method of treating a condition or disorder by inhibiting fatty acid amidohydrolase in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I or a compound having the structure
    Figure US20050131032A1-20050616-C00016
  • According to various embodiment of a seventh aspect of the present invention is provided a method of treating a condition or disorder by inhibiting fatty acid amidohydrolase in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. According to various embodiments of a eighth aspect of the present invention is provided a method of treating neuropathic pain in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of a ninth aspect of the present invention is provided a method of treating acute pain in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of a tenth aspect of the present invention is provided a method of treating chronic pain in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of an eleventh aspect of the present invention is provided a method of treating emesis in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of a twelfth aspect of the present invention is provided a method of treating anxiety in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of a thirteenth aspect of the present invention is provided a method of altering feeding behaviors in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of a fourteenth aspect of the present invention is provided a method of treating movement disorders in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of a fifteenth aspect of the present invention is provided a method treating glaucoma in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of a sixteenth aspect of the present invention is provided a method of treating brain injury in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of a seventeenth aspect of the present invention is provided a method of treating cardiovascular disease in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
  • According to various embodiments of an eighteenth aspect of the present invention is provided a pharmaceutical composition for treating a condition or disorder requiring inhibition of a fatty acid amidohydrolase comprising a therapeutically effective amount of a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or diluent.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a novel series of compounds of Formula I, its hydrates and solvates thereof:
    Figure US20050131032A1-20050616-C00017
    or a pharmaceutically acceptable salt or solvate thereof,
    wherein
    • A is dibenzofuranyl, dibenzothienyl, naphthyl, indolyl, fluorenyl, carbazolyl, or represented by Formula II:
      Figure US20050131032A1-20050616-C00018
      wherein
    • a is 1 or 2,
    • R is C1-16 alkoxy optionally substituted with phenyl, pyridyl or morpholinyl; phenyl optionally substituted with C1-4 alkyl; phenoxy; phenyl-C1-4 alkyloxy-; pyridyloxy; pyridyl-C1-4 alkyloxy-; —N(H)—C(O)—C1-16 alkyl; or —C(O)—N(H)—C1-16 alkyl;
    • R1 is a bond or a C1-3 branched or linear aliphatic hydrocarbon; and
    • B is C1-4 alkyl, indolyl, benzofuranyl, benzothienyl, dibenzofuranyl, dibenzothienyl, fluorenyl, carbazolyl, napthyl, quinolinyl or isoquinolinyl, wherein each is optionally substituted with one or more of the same or different substituent selected from the group consisting of C1-4 branched or linear aliphatic hydrocarbon, C1-4 alkoxy, halo, haloalkyl, nitro and (C1-3 alkyl)0-2 amino- or represented by Formula III or Formula IV:
      Figure US20050131032A1-20050616-C00019
      wherein
    • R2 is hydrogen, methyl,
    • R3 is C1-4 alkyl, pyridyl, or phenyl optionally substituted with one or more of the same or different substituents selected from the group consisting of halo,
    • C1-4haloalkyl and nitro,
    • X is CH or nitrogen,
    • R4 is C1-4 branched or linear aliphatic hydrocarbon, C1-4 alkoxy, halo, haloalkyl, nitro or amino, and
    • b is 0 to 3.
  • Preferably, A is represented by Formula II:
    Figure US20050131032A1-20050616-C00020
    wherein a is 1, R is C1-12 alkoxy; phenoxy; pyridyloxy; or amido optionally substituted with C1-16 alkyl; and R1 is a bond.
  • When B is represented by Formula III:
    Figure US20050131032A1-20050616-C00021
    R2 is preferably hydrogen or methyl, and R3 is preferably methyl, or phenyl optionally substituted with one or more halo, haloalkyl or nitro.
  • When B is represented by Formula IV:
    Figure US20050131032A1-20050616-C00022
    X is preferably CH, R4 is preferably halo, and b is 1. When X is nitrogen, however, b is preferably 0.
  • When B is represented by Formula V:
    Figure US20050131032A1-20050616-C00023
    X is preferably nitrogen.
  • The description of the invention herein should be construed in congruity with the laws and principals of chemical bonding. For example, when a moiety is optionally substituted and said substitution requires the removal of a hydrogen atom from the moiety to be substituted, the description of the moiety should be read to include the moiety with or without said hydrogen atom. As another example, if a variable is defiried as a particular moiety or atom and is further defined to have value of 0 or some integer, the bond(s) attaching said moiety should be suitably removed in the event the variable equals 0.
  • An embodiment or aspect which depends from another embodiment or aspect, will describe only the variables having values and provisos that differ from the embodiment or aspect from which it depends. For example, if a dependnent embodiment describes a variable as being “phenyl or pyridyl”, wherein said phenyl and pyridyl were described in the independent embodiment as being “optionally substituted”, then the phenyl and pyridyl of the dependent embodiment will also be optionally substituted.
  • It is to be understood that the present invention may include any and all possible stereoisomers, geometric isomers, diastereoisomers, enantiomers, anomers and optical isomers, unless a particular description specifies otherwise. More particularly, the groups attached to the oxime portion of compounds of Formula (I), i.e., N═C, may assume transoid or cisoid configurations.
  • As used herein, “halo” or “halogen” includes fluoro, chloro, bromo and iodo. As used herein, “alkyl” or “alkylene” includes straight or branched chain configurations.
  • The compounds of this invention can exist in the form of pharmaceutically acceptable salts. Such salts include addition salts with inorganic acids such as, for example, hydrochloric acid and sulfuric acid, and with organic acids such as, for example, acetic acid, citric acid, methanesulfonic acid, toluenesulfonic acid, tartaric acid and maleic acid. Further, in case the compounds of this invention contain an acidic group, the acidic group can exist in the form of alkali metal salts such as, for example, a potassium salt and a sodium salt; alkaline earth metal salts such as, for example, a magnesium salt and a calcium salt; and salts with organic bases such as a triethylammonium salt and an arginine salt. The compounds of the present invention may be hydrated or non-hydrated.
  • The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. The compounds of this invention may also be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, all using dosage forms well known to those skilled in the pharmaceutical arts. The compounds can be administered alone, but generally will be administered with a pharmaceutical carrier selected upon the basis of the chosen route of administration and standard pharmaceutical practice. Compounds of this invention can also be administered in intranasal form by topical use of suitable intranasal vehicles, or by transdermal routes, using transdermal skin patches. When compounds of this invention are administered transdermally the dosage will be continuous throughout the dosage regimen.
  • The dosage and dosage regimen and scheduling of a compounds of the present invention must in each case be carefully adjusted, utilizing sound professional judgment and considering the age, weight and condition of the recipient, the route of administration and the nature and extent of the disease condition. In accordance with good clinical practice, it is preferred to administer the instant compounds at a concentration level that will produce effective beneficial effects without causing any harmful or untoward side effects.
  • Compounds of the present invention may be synthesized according to the description provided below. Variables provided in the schema below are defined in accordance with the description of compounds of Formula (I) unless otherwise specified.
    • EXPERIMENTALS
  • Figure US20050131032A1-20050616-C00024
  • Scheme 1 Reaction conditions: (i) R-halide, NaH, DMF, room temp.; (ii) NaOH, EtOH, room temp., (iii) (a) N3P(O)(OPh)2, Et3N, toluene at 105° C., (b) addition of oxime C at 80° C.; n is 0 to 3; R, R2, R3, and B are as defined above.
    Figure US20050131032A1-20050616-C00025
  • Scheme 1A Reaction conditions: (i) R-halide, NaH, DMF, room temp.; (ii) NaOH, EtOH, room temp., (iii) (a) N3P(O)(OPh)2, Et3N, toluene at room temp. following by 90 min. at reflux, (b) addition of oxime C at room temp. with stirring for 1 hr., heating to 85° C.; n is 0 to 3; R, and R2 are as defined above.
    Figure US20050131032A1-20050616-C00026
  • Scheme 1B Reaction conditions: (iv) (a) N3P(O)(OPh)2, Et3N, toluene at 105° C., (b) B-OH at 80° C.; n is 0 to 3; R and B are as defined above. The following Intermediates 1 to 39 may be used to synthesize Examples 1 to 124 in accordance with Schemes 1, 1A and 1B.
    • Intermediate 1
  • Figure US20050131032A1-20050616-C00027
  • 4-Propoxy-benzoic acid ethyl ester: (Scheme 1, Compound A) To a solution of ethyl 4-hydroxybenzoate (2.0 g, 12 mmol) and bromopropane (4.0 g, 32.8 mmol) in DMF (50 mL) was added NaH (60% in mineral oil, 0.80 g, 20.8 mmol). The resultant suspension was stirred at room temperature for 1.0 hour. The mixture was diluted with ethyl acetate (EtOAc) (300 mL), washed with H2O, and then was dried over Na2SO4. After filtration and concentration in vacuo, the residue was purified by flash chromatography (SiO2: EtOAc/Hexanes). This compound was obtained as a yellow oil (2.26 g, 10.9 mmol, 91% yield). 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.24 (q, 2H, J=6.9 Hz), 3.98 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (t, 3H, J=6.6 Hz), 0.97 (t, 3H, J=7.2 Hz); Anal. Calcd for C12H16O3.0.47 C6H14: C, 71.54; H, 9.14; N, 0.00. Found: C, 71.57; H, 8.78, N, 0.00; Mass Spec.: 209.04 (MH+).
    • Intermediate 2
  • Figure US20050131032A1-20050616-C00028
  • 4-Ethoxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=9.0 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.24 (q, 2H, J=6.9 Hz), 4.08 (q, 2H, J=6.9 Hz), 1.31 (m, 6H); Anal. Calcd for C11H14O3.0.47C6H14: C, 70.71; H, 8.83; N, 0.00; Found: C, 71.10; H, 8.43, N, 0.00; Mass Spec.: 194.93 (MH+).
    • Intermediate 3
  • Figure US20050131032A1-20050616-C00029
  • 4-Pentyloxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.24 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 7H, J=6.6 Hz), 0.97 (t, 3H, J=7.2 Hz); Anal. Calcd for C14H20O3.0.37C6H14: C, 72.63; H, 9.46; N, 0.00; Found: C, 72.69; H, 9.12, N, 0.00; Mass Spec.: 237.11 (MH+).
    • Intermediate 4
  • Figure US20050131032A1-20050616-C00030
  • 4-Butoxy-3-methoxy-benzoic acid methyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.57 (dd, 1H, J=8.4, 1.8 Hz), 7.43 (d, 1H, J=1.8 Hz), 7.06 (d, 1H, J=8.4 Hz), 4.02 (q, 2H, J=6.6 Hz), 3.82 (s, 3H), 3.80 (s, 3H), 1.72 (m, 2H), 1.44 (m, 2H), 0.92 (t, 3H, J=7.5 Hz); Mass Spec.: 239.21 (MH+).
    • Intermediate 5
  • Figure US20050131032A1-20050616-C00031
  • 4-Hexyloxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.26 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 9H), 0.89 (t, 3H, J=7.2 Hz); Mass Spec.: 251 (MH+).
    • Intermediate 6
  • Figure US20050131032A1-20050616-C00032
  • 4-Heptyloxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.26 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 11 H), 0.85 (t, 3H, J=7.2 Hz); Mass Spec.: 265 (MH+).
    • Intermediate 7
  • Figure US20050131032A1-20050616-C00033
  • 4-Octyloxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.26 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 13H), 0.84 (t, 3H, J=7.2 Hz); Mass Spec.: 279.36 (MH+).
    • Intermediate 8
  • Figure US20050131032A1-20050616-C00034
  • 4-Nonyloxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.26 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 15H), 0.84 (t, 3H, J=7.2 Hz); Mass Spec.: 293.32 (MH+).
    • Intermediate 9
  • Figure US20050131032A1-20050616-C00035
  • 4-Decyloxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.26 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 17H), 0.83 (t, 3H, J=7.2 Hz); Mass Spec.: 307.27 (MH+).
    • Intermediate 10
  • Figure US20050131032A1-20050616-C00036
  • 4-Undecyloxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.26 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 19H), 0.83 (t, 3H, J=7.2 Hz); Mass Spec.: 321.28 (MH+).
    • Intermediate 11
  • Figure US20050131032A1-20050616-C00037
  • 4-Dodecyloxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.26 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 21H), 0.83 (t, 3H, J=6.6 Hz); Mass Spec.: 335.29 (MH+).
    • Intermediate 12
  • Figure US20050131032A1-20050616-C00038
  • 4-(3-Morpholin-4-yl-propoxy)-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.26 (q, 2H, J=6.9 Hz), 4.08 (t, 2H, J=6.6 Hz), 3.56 (t, 4H, J=4.5 Hz), 2.36 (m, 6H), 1.72 (m, 2H), 1.32 (m, 2H), 1.29 (t, 3H, J=6.9 Hz); Mass Spec.: 294.32 (MH+).
    • Intermediate 13
  • Figure US20050131032A1-20050616-C00039
  • (4-Butoxy-phenyl)-acetic acid methyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.16 (dd, 2H, J=6.6, 1.8 Hz), 6.85 (dd, 2H, J=6.6, 1.8 Hz), 3.93 (t, 2H, J=6.3 Hz), 3.59 and 3.58 (5H, CH2, CH3), 1.67 (m, 2H), 1.40 (m, 2H), 0.92 (t, 3H, J=7.2 Hz).
    • Intermediate 14
  • Figure US20050131032A1-20050616-C00040
  • 3-Butoxy-benzoic acid ethyl ester: (Scheme 1, Compound A) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.53 (dd, 1H, J=7.8, 1.5 Hz), 7.42 (m, 2H), 7.20 (dd, 1H, J=8.4, 1.5 Hz), 4.31 (q, 2H, J=6.9 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.47 (m, 2H), 1.32 (t, 3H, J=6.9 Hz), 0.93 (t, 3H, J=7.5 Hz); Mass Spec.: 223.24 (MH+).
    • Intermediate 15
  • Figure US20050131032A1-20050616-C00041
  • 4-Butoxy-benzoic acid: (Scheme 1, Compound B) To a solution of ethyl 4-butoxybenzoate (2.0 g, 9.6 mmol) in EtOH (30 mL) was added NaOH (10 N, 6 mL, 60 mmol). The resulting mixture was stirred at room temperature for 3 hours, diluted with H2O (30 mL), acidified to about pH 1.0 using HCl (6N). The precipitates were filtered off by filter paper, washed by H2O and hexanes. This compound was obtained as a white solid. (1.63 g, 9.1 mmol, 94% yield). 1H NMR (DMSO-d6) δ 12.59 (br. s, 1H), 7.88 (d, 2H, J=9.5 Hz), 6.97 (d, 2H, J=9.5 Hz), 4.01 (t, 2H, J=6.5 Hz), 1.68 (m, 2H), 1.42 (m, 2H), 0.91 (t, 3H, J=6.5 Hz); 13C NMR (DMSO): 166.9, 162.2, 131.2, 122.7, 114.0, 67.3, 30.5, 18.6 and 13.5; Mass Spec.: 195.17 (MH+).
    • Intermediate 16
  • Figure US20050131032A1-20050616-C00042
  • 4-Pentyloxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.59 (br, s, 1 H), 7.88 (d, 2H, J=9.6 Hz), 6.97 (d, 2H, J=9.6 Hz), 4.01 (t, 2H, J=6.9 Hz), 1.69 (m, 2H), 1.32 (m, 4H), 0.89 (t, 3H, J=6.9 Hz); Mass Spec.: 209.23 (MH+).
    • Intermediate 17
  • Figure US20050131032A1-20050616-C00043
  • 4-Propoxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.6 (br, s, 1H), 7.88 (d, 2H, J=9.6 Hz), 6.97 (d, 2H, J=9.6 Hz), 4.01 (t, 2H, J=6.9 Hz), 1.72 (m, 2H), 0.97 (t, 3H, J=7.5 Hz); Mass Spec.: 181.18 (MH+).
    • Intermediate 18
  • Figure US20050131032A1-20050616-C00044
  • 4-Ethoxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.59 (br. s, 1H), 7.88 (d, 2H, J=9.6 Hz), 6.97 (d, 2H, J=9.6 Hz), 4.08 (q, 2H, J=7.2 Hz), 1.33 (t, 3H, J=6.9 Hz); Mass Spec.: 167.13 (MH+).
    • Intermediate 19
  • Figure US20050131032A1-20050616-C00045
  • 4-Butoxy-3-methoxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.6 (br, s,1H), 7.54 (dd, 1H, J=8.4, 1.8 Hz), 7.43 (d, 1H, J=1.8 Hz), 7.06 (d, 1H, J=8.4 Hz), 4.02 (q, 2H, J=6.6 Hz), 3.80 (s, 3H), 1.72 (m, 2H), 1.44 (m, 2H), 0.92 (t, 3H, J=7.5 Hz).
    • Intermediate 20
  • Figure US20050131032A1-20050616-C00046
  • 4-Hexyloxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.59 (s, 1H), 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 6H), 0.89 (t, 3H, J=7.2 Hz); Mass Spec.: 223 (MH+).
    • Intermediate 21
  • Figure US20050131032A1-20050616-C00047
  • 4-Heptyloxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.59 (s, 1 H), 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 8H), 0.85 (t, 3H, J=7.2 Hz); Mass Spec.: 237.16 (MH+).
    • Intermediate 22
  • Figure US20050131032A1-20050616-C00048
  • 4-Octyloxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 1OH), 0.84 (t, 3H, J=7.2 Hz); Mass Spec.: 251.11 (MH+).
    • Intermediate 23
  • Figure US20050131032A1-20050616-C00049
  • 4-Nonyloxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.58 (s, 1 H), 7.89 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 12H), 0.84 (t, 3H, J=7.2 Hz).
    • Intermediate 24
  • Figure US20050131032A1-20050616-C00050
  • 4-Dodecyloxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.6 (s, 1 H), 7.86 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 18H), 0.84 (t, 3H, J=6.6 Hz).
    • Intermediate 25
  • Figure US20050131032A1-20050616-C00051
  • 4-Undecyloxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.6 (s,1 H), 7.86 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 16H), 0.84 (t, 3H, J=6.6 Hz).
    • Intermediate 26
  • Figure US20050131032A1-20050616-C00052
  • 4-Decyloxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.6 (s, 1 H), 7.86 (d, 2H, J=8.7 Hz), 7.00 (d, 2H, J=9.0 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.29 (m, 14H), 0.84 (t, 3H, J=6.6 Hz).
    • Intermediate 27
  • Figure US20050131032A1-20050616-C00053
  • 4-(3-Morpholin-4-yl-propoxy)-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.78 (d, 2H, J=8.4 Hz), 6.79 (d, 2H, J=8.4 Hz), 4.08 (t, 2H, J=6.6 Hz), 3.56 (t, 4H, J=4.5 Hz), 2.36 (m, 6H), 1.85 (m, 2H).
    • Intermediate 28
  • Figure US20050131032A1-20050616-C00054
  • (4-Butoxy-phenyl)-acetic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 12.21 (br. s, 1H), 7.16 (dd, 2H, J=6.6, 1.8 Hz), 6.85 (dd, 2H, J=6.6, 1.8 Hz), 3.93 (t, 2H, J=6.3 Hz), 3.46 (s, 2H), 1.69 (m, 2H), 1.43 (m, 2H), 0.92 (t, 3H, J=7.2 Hz).
    • Intermediate 29
  • Figure US20050131032A1-20050616-C00055
  • 3-Butoxy-benzoic acid: (Scheme 1, Compound B) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.53 (dd, 1H, J=7.8, 1.5 Hz), 7.42 (m, 2H), 7.17 (dd, 1H, J=8.4, 1.5 Hz), 4.01 (t, 2H, J=6.6 Hz), 1.72 (m, 2H), 1.47 (m, 2H), 0.93 (t, 3H, J=7.2 Hz).
    • Intermediate 30
  • Figure US20050131032A1-20050616-C00056
  • 2,4-Difluoro-benzaldehyde oxime: (Scheme 1, Compound C) To a mixture of 2,4-difluorobenzaldehyde (0.80 g, 5.6 mmol) and hydroxyamine HCl salt (0.43 g, 6.2 mmol) in EtOH (5 mL) was added K2CO3 (0.85 g, 6.2 mmol). The resultant mixture was stirred at rt for 24 hours. The mixture was diluted with MeOH (20 mL). The precipitates were filter off and washed with MeOH. The product from filtrate was purified by recrystalization (EtOAc/Hexanes). This compound was obtained as a white solid (0.84 g, 5.3 mmol, 94% yield).
  • 1H NMR (DMSO-d6) δ 12.98 (br. s, 1H), 8.17 (s, 1H), 7.79 (m, 1H), 7.32 (m, 1H), 7.11 (m, 1H); Analytical HPLC 1.03 min. (95%); Mass Spec.: 158.06 (MH+).
    • Intermediate 31
  • Figure US20050131032A1-20050616-C00057
  • 2-Fluoro-6-trifluoromethyl-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 11.96 (br. s, 1H), 8.21 (m, 1H), 7.65 (m, 3H); Analytical HPLC 1.20 min. (96%); Mass Spec.: 208.14 (MH+).
    • Intermediate 32
  • Figure US20050131032A1-20050616-C00058
  • 3,4-Difluoro-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. Analytical HPLC 1.00 min. (92%); Mass Spec.: 158 (MH+).
    • Intermediate 33
  • Figure US20050131032A1-20050616-C00059
  • 3-Fluoro-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. Analytical HPLC 0.90 min. (95%); Mass Spec.: 138 (MH−).
    • Intermediate 34
  • Figure US20050131032A1-20050616-C00060
  • 4-Trifluoromethyl-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. Analytical HPLC 1.31 min. (95%); Mass Spec.: 188.01 (MH+).
    • Intermediate 35
  • Figure US20050131032A1-20050616-C00061
  • 2-Fluoro-3-trifluoromethyl-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. Analytical HPLC 1.41 min. (90%); Mass Spec.: 206.00 (MH−).
    • Intermediate 36
  • Figure US20050131032A1-20050616-C00062
  • 2,3,5,6-Tetrafluoro-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. Analytical HPLC 0.83 min. (96%); Mass Spec.: 191.98 (MH−).
    • Intermediate 37
  • Figure US20050131032A1-20050616-C00063
  • 2,6-Difluoro-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. Analytical HPLC 0.86 min. (95%); Mass Spec.: 158.05 (MH+).
    • Intermediate 38
  • Figure US20050131032A1-20050616-C00064
  • 2,3-Difluoro-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. Analytical HPLC 0.83 min. (90%); Mass Spec.: 156.04 (MH−).
    • Intermediate 39
  • Figure US20050131032A1-20050616-C00065
  • 2,4,5-Trifluoro-benzaldehyde oxime: (Scheme 1, Compound C) Prepared as described for the example above. Analytical HPLC 0.89 min. (91%); Mass Spec.: 174.00 (MH−).
    • EXAMPLE 1
  • Figure US20050131032A1-20050616-C00066
  • 3-Pyridinecarboxaldehyde, O-[[[4-(Heptyloxy)phenyl]amino]-carbonyl]oxime (Scheme 1, Compound D) To a solution of 4-heptyloxybenzoic acid (0.20 g, 0.85 mmol) and Et3N (0.18 g, 1.8 mmol) in toluene (5 mL) was added diphenylphosphoryl azide (0.322 g, 1.2 mmol). The resultant mixture was stirred at r.t. for 10 min. and then at 105° C. under N2 for 60 min. After the mixture was cooled to r.t., 3-pyridinealdoxime (0.20 g, 1.7 mmol) was added. The reaction mixture was stirred at r.t. for 10 min. and then at 80° C. for 1 h. The product (free base) was purified by flash chromatography (SiO2: EtOAc/Hexanes) and then was dissolved in a solution of TFA in THF (5.0 mg/mL, 17.8 mL, 0.78 mmol). Removal of solvent provided this compound (TFA salt) as a pale yellow solid (0.244 g, 0.52 mmol, 61% yield). 1H NMR (DMSO-d6) δ 9.72 (s, 1H), 8.99 (s, 1H), 8.72 (m, 2H), 8.32 (d, 1H, J=9.0 Hz) 7.56 (m, 1H), 7.40 (d, 2H, J=8.5 Hz), 6.91 (d, 2H, J=6.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.72 (m, 2H), 1.32 (m, 8H), 0.87 (t, 3H, J=7.0 Hz); Anal. Calcd for C20H25N3O3.0.98 C2F3O2H1: C, 56.44; H, 5.60; N, 8.99. Found: C, 56.41; H, 5.64, N, 8.94. Mass Spec: 356.28 (MH+).
    • EXAMPLE 2
  • Figure US20050131032A1-20050616-C00067
  • (4-Butoxyphenyl)methylcarbamic acid, 3-pyridinyl ester (Scheme 1, Compound D) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 8.51 (m, 3H), 7.75 (m, 1H), 7.55 (m, 1H), 7.24 (d, 2H, J=9.0 Hz), 6.91 (d, 2H, J=8.7 Hz), 4.22 (d, 2H, J=6.0), 3.92 (t, 2H, J=6.6 Hz), 1.70 (m, 2H), 1.36 (m, 2H), 0.92 (t, 3H, J=7.5 Hz); Anal. Calcd for C17H20N2O3.1.55 C2F3O2H1: C, 50.64; H, 4.56; N, 5.88. Found: C, 50.49; H, 4.58, N, 5.73. Mass Spec: 301.17 (MH+).
    • EXAMPLE 3
  • Figure US20050131032A1-20050616-C00068
  • 3-Pyridinecarboxaldehyde, O-[[[4-(undecyloxy)phenyl]amino]-carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.72 (s, 1H), 8.99 (s, 1H), 8.72 (m, 2H), 8.32 (d, 1H, J=9.0 Hz), 7.56 (m, 1H), 7.40 (d, 2H, J=8.5 Hz), 6.91 (d, 2H, J=6.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.72 (m, 2H), 1.32 (m, 16 H), 0.87 (t, 3H, J=7.0 Hz). Mass Spec: 412.33 (MH+).
    • EXAMPLE 4
  • Figure US20050131032A1-20050616-C00069
  • 3-Pyridinecarboxaldehyde, O-[[[4-(nonyloxy)phenyl]amino]-carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.72 (s, 1 H), 8.99 (s, 1H), 8.72 (m, 2H), 8.32 (d, 1H, J=9.0 Hz), 7.56 (m,1H), 7.40 (d, 2H, J=8.5 Hz), 6.91 (d, 2H, J=6.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.72 (m, 2H), 1.32 (m, 12 H), 0.87 (t, 3H, J=7.0 Hz). Mass Spec: 384.89 (MH+).
    • EXAMPLE 5
  • Figure US20050131032A1-20050616-C00070
  • 4-Fluorobenzaldehyde, O-[[(4-butoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above in a form of free base. No trifluoroacetic acid was used. 1H NMR (DMSO-d6) δ 9.66 (s, 1H), 8.64 (s, 1H), 7.90 (m, 2H), 7.38 (m, 2H), 7.34 (t, 2H, J=6.0 Hz, 6.92 (d, 2H, J=4.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.72 (m, 2H), 1.40 (m, 2H), 0.92 (t, 3H, J=7.5 Hz); Anal. Calcd for C18H19FN203: C, 65.44; H, 5.79; N, 8.48. Found: C, 65.48; H, 5.88, N, 8.46. Mass Spec: 331.14 (MH+).
    • EXAMPLE 6
  • Figure US20050131032A1-20050616-C00071
  • 2-Propanone, O-[[(4-ethoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. This compound was purified by preparative HPLC (YMC 30×100 mm (5 uM packing), 10% MeOH/90% water/01% TFA as mobile phase A, 90% MeOH/10%water/0.1% TFA as mobile phase B). Analytical HPLC 1.10 min. (95%). Mass Spec: 237 (MH+).
    • EXAMPLE 7
  • Figure US20050131032A1-20050616-C00072
  • 2-Propanone, O-[[(4-propoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.36 (s, 1H), 7.34 (d, 2H, J=9.0 Hz), 6.85 (dd, 2H, J=6.9, 2.1 Hz), 3.87 (t, 2H, J=6.9 Hz), 1.97 (s, 6H), 1.72 (m, 2H), 0.96 (t, 3H, J=7.5 Hz); Analytical HPLC 1.27 min. (95%). Mass Spec: 251.24 (MH+).
    • EXAMPLE 8
  • Figure US20050131032A1-20050616-C00073
  • 2-Propanone, O-[[(4-pentyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.67 min. (95%). Mass Spec: 279.18 (MH+).
    • EXAMPLE 9
  • Figure US20050131032A1-20050616-C00074
  • Benzaldehyde, O-[[(4-ethoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.41 min. (85%). Mass Spec: 285.21 (MH+).
    • EXAMPLE 10
  • Figure US20050131032A1-20050616-C00075
  • Benzaldehyde, O-[[(4-propoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.64 min. (85%). Mass Spec: 299.15 (MH+).
    • EXAMPLE 11
  • Figure US20050131032A1-20050616-C00076
  • Benzaldehyde, O-[[(4-pentyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.85 min. (95%). Mass Spec: 327.20 (MH+).
    • EXAMPLE 12
  • Figure US20050131032A1-20050616-C00077
  • 4-Fluorobenzaldehyde, O-[[(4-ethoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.66 (s,1H), 8.64 (s, 1H), 7.90 (m, 2H), 7.38 (m, 4H), 6.90 (d, 2H, J=4.5 Hz), 3.92 (q, 2H, J=6.5 Hz), 1.31 (t, 3H, J=7.2 Hz). Analytical HPLC 1.46 min. (95%). Mass Spec: 303 (MH+).
    • EXAMPLE 13
  • Figure US20050131032A1-20050616-C00078
  • 4-Fluorobenzaldehyde, O-[[(4-propoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.67 min. (94%). Mass Spec: 317 (MH+).
    • EXAMPLE 14
  • Figure US20050131032A1-20050616-C00079
  • 4-Fluorobenzaldehyde, O-[[(4-pentyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.76 min. (97%). Mass Spec: 345.24 (MH+).
    • EXAMPLE 15
  • Figure US20050131032A1-20050616-C00080
  • 3-Pyridinecarboxaldehyde, O-[[(4-ethoxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLCO.99 min. (95%). Mass Spec: 286.24 (MH+).
    • EXAMPLE 16
  • Figure US20050131032A1-20050616-C00081
  • 3-Pyridinecarboxaldehyde, O-[[(4-propoxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.28 min. (95%). Mass Spec: 300.15 (MH+).
    • EXAMPLE 17
  • Figure US20050131032A1-20050616-C00082
  • 3-Pyridinecarboxaldehyde, O-[[(4-pentyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.50 min. (95%). Mass Spec: 328.27 (MH+).
    • EXAMPLE 18
  • Figure US20050131032A1-20050616-C00083
  • 2-Propanone, O-[[(4-butoxy-3-methoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.35 min. (98%). Mass Spec: 295.27 (MH+).
    • EXAMPLE 19
  • Figure US20050131032A1-20050616-C00084
  • Benzaldehyde, O-[[(4-butoxy-3-methoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.59 min. (99%). Mass Spec: 343 (MH+).
    • EXAMPLE 20
  • Figure US20050131032A1-20050616-C00085
  • 4-Fluorobenzaldehyde, O-[[(4-butoxy-3-methoxyphenyl)amino]-carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.61 min. (95%). Mass Spec: 361.24 (MH+).
    • EXAMPLE 21
  • Figure US20050131032A1-20050616-C00086
  • 3-Pyridinecarboxaldehyde, O-[[(4-butoxy-3-methoxyphenyl)amino]-carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.27 min. (99%). Mass Spec: 344.30 (MH+).
    • EXAMPLE 22
  • Figure US20050131032A1-20050616-C00087
  • 2-Propanone, O-[[(4-hexyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.70 min. (94%). Mass Spec: 293 (MH+).
    • EXAMPLE 23
  • Figure US20050131032A1-20050616-C00088
  • Benzaldehyde, O-[[(4-hexyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.84 min. (99%). Mass Spec: 341.26 (MH+).
    • EXAMPLE 24
  • Figure US20050131032A1-20050616-C00089
  • 4-Fluorobenzaldehyde, O-[[(4-hexyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.86 min. (99%). Mass Spec: 359.22 (MH+).
    • EXAMPLE 25
  • Figure US20050131032A1-20050616-C00090
  • 3-Pyridinecarboxaldehyde, O-[[(4-hexyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.64 min. (90%). Mass Spec: 342.30 (MH+).
    • EXAMPLE 26
  • Figure US20050131032A1-20050616-C00091
  • 2-Propanone, O-[[(4-heptyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.98 min. (91%). Mass Spec: 307.19 (MH+).
    • EXAMPLE 27
  • Figure US20050131032A1-20050616-C00092
  • Benzaldehyde, O-[[(4-heptyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.11 min. (93%). Mass Spec: 355.18 (MH+).
    • EXAMPLE 28
  • Figure US20050131032A1-20050616-C00093
  • 4-Fluorobenzaldehyde, O-[[(4-heptyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.10 min. (90%). Mass Spec: 373.11 (MH+).
    • EXAMPLE 29
  • Figure US20050131032A1-20050616-C00094
  • 2-Propanone, O-[[(4-octyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.89 min. (87%). Mass Spec: 321 (MH+).
    • EXAMPLE 30
  • Figure US20050131032A1-20050616-C00095
  • 3-Pyridinecarboxaldehyde, O-[[(4-octyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.0 min. (85%). Mass Spec: 370.13 (MH+).
    • EXAMPLE 31
  • Figure US20050131032A1-20050616-C00096
  • 2-Propanone, O-[[(4-nonyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.64 min. (97%). Mass Spec: 335.31 (MH+).
    • EXAMPLE 32
  • Figure US20050131032A1-20050616-C00097
  • 2-Propanone, O-[[(4-decyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.03 min. (99%). Mass Spec: 349.35 (MH+).
    • EXAMPLE 33
  • Figure US20050131032A1-20050616-C00098
  • Benzaldehyde, O-[[(4-decyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.10 min. (99%). Mass Spec: 397.38 (MH+).
    • EXAMPLE 34
  • Figure US20050131032A1-20050616-C00099
  • 4-Fluorobenzaldehyde, O-[[(4-decyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.11 min. (97%). Mass Spec: 415.34 (MH+).
    • EXAMPLE 35
  • Figure US20050131032A1-20050616-C00100
  • 3-Pyridinecarboxaldehyde, O-[[(4-decyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.01 min. (85%). Mass Spec: 398.34 (MH+).
    • EXAMPLE 36
  • Figure US20050131032A1-20050616-C00101
  • 2-Propanone, O-[[(4-undecyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.25 min. (90%). Mass Spec: 363.26 (MH+).
    • EXAMPLE 37
  • Figure US20050131032A1-20050616-C00102
  • Benzaldehyde, O-[[(4-undecyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.36 min. (96%). Mass Spec: 411.28 (MH+).
    • EXAMPLE 38
  • Figure US20050131032A1-20050616-C00103
  • 4-Fluorobenzaldehyde, O-[[(4-undecyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.37 min. (97%). Mass Spec: 429.30 (MH+).
    • EXAMPLE 39
  • Figure US20050131032A1-20050616-C00104
  • Benzaldehyde, O-[[(4-butoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.66 (s, 1H), 8.62 (s, 1H), 7.82 (m, 2H), 7.52 (m, 3H), 7.40 (d, 2H, J=8.5 Hz), 6.90 (d, 2H, J=9.0 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.72 (m, 2H), 1.40 (m, 2H), 0.92 (t, 3H, J=7.5 Hz); Analytical HPLC 1.67 min. (90%). Mass Spec: 313.15 (MH+).
    • EXAMPLE 40
  • Figure US20050131032A1-20050616-C00105
  • 2-Propanone, O-[[(4-dodecyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.15 min. (99%). Mass Spec: 377.43 (MH+).
    • EXAMPLE 41
  • Figure US20050131032A1-20050616-C00106
  • Benzaldehyde, O-[[(4-dodecyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.20 min. (99%). Mass Spec: 425.41 (MH+).
    • EXAMPLE 42
  • Figure US20050131032A1-20050616-C00107
  • 4-Fluorobenzaldehyde, O-[[(4-dodecyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.21 min. (99%). Mass Spec: 443.37 (MH+).
    • EXAMPLE 43
  • Figure US20050131032A1-20050616-C00108
  • 3-Pyridinecarboxaldehyde, O-[[dodecyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.27 min. (85%). Mass Spec: 426.32 (MH+).
    • EXAMPLE 44
  • Figure US20050131032A1-20050616-C00109
  • 3-Pyridinecarboxaldehyde, O-[[(4-butoxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.48 min. (95%). Mass Spec: 314.20 (MH+).
    • EXAMPLE 45
  • Figure US20050131032A1-20050616-C00110
  • Benzaldehyde, O-[[(4-octyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.99 min. (99%). Mass Spec: 369.27 (MH+).
    • EXAMPLE 46
  • Figure US20050131032A1-20050616-C00111
  • 4-Fluorobenzaldehyde, O-[[(4-octyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.99 min. (96%). Mass Spec: 387.39 (MH+).
    • EXAMPLE 47
  • Figure US20050131032A1-20050616-C00112
  • Benzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.04 min. (95%). Mass Spec: 383.30 (MH+).
    • EXAMPLE 48
  • Figure US20050131032A1-20050616-C00113
  • 4-Fluorobenzaldehyde, o-[[(4-nonyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.0 min. (95%). Mass Spec: 401.30 (MH+).
    • EXAMPLE 49
  • Figure US20050131032A1-20050616-C00114
  • 3,4-Difluorobenzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.66 (s, 1H), 8.62 (s, 1H), 7.90 (m, 1H), 7.65 (m, 2H), 7.40 (d, 2H, J=8.7 Hz), 6.90 (d, 2H, J=9.0 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.72 (m, 2H), 1.25 (m, 12H), 0.85 (t, 3H, J=7.5 Hz). Analytical HPLC 2.03 min. (95%). Mass Spec: 419.20 (MH+).
    • EXAMPLE 50
  • Figure US20050131032A1-20050616-C00115
  • 2,6-Difluorobenzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.05 min. (85%). Mass Spec: 419 (MH+).
    • EXAMPLE 51
  • Figure US20050131032A1-20050616-C00116
  • 2,4-Difluorobenzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.07 min. (99%). Mass Spec: 419.31 (MH+).
    • EXAMPLE 52
  • Figure US20050131032A1-20050616-C00117
  • 3-Fluorobenzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.05 min. (95%). Mass Spec: 401.33 (MH+).
    • EXAMPLE 53
  • Figure US20050131032A1-20050616-C00118
  • 4-(Trifluoromethyl)benzaldehyde, O-[[(4-nonyloxyphenyl)amino]-carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.64 min. (99%). Mass Spec: 451.25 (MH+).
    • EXAMPLE 54
  • Figure US20050131032A1-20050616-C00119
  • 2-Fluoro-3-(trifluoromethyl)benzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.11 min. (85%). Mass Spec: 469.07 (MH+).
    • EXAMPLE 55
  • Figure US20050131032A1-20050616-C00120
  • 2,3-Difluorobenzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.08 min. (90%). Mass Spec: 419.17 (MH+).
    • EXAMPLE 56
  • Figure US20050131032A1-20050616-C00121
  • 2,4,5-Trifluorobenzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.01 min. (95%). Mass Spec: 437 (MH+).
    • EXAMPLE 57
  • Figure US20050131032A1-20050616-C00122
  • 2-Fluoro-5-(trifluoromethyl)benzaldehyde, O-[[(4-nonyloxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.11 min. (95%). Mass Spec: 469.13 (MH+).
    • EXAMPLE 58
  • Figure US20050131032A1-20050616-C00123
  • 4-Fluorobenzaldehyde, O-[[4-[3-(4-morpholinyl)propoxyphenyl]amino]carbony]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 2.68 min. (85%). Mass Spec: 402.30 (MH+).
    • EXAMPLE 59
  • Figure US20050131032A1-20050616-C00124
  • 4-Nitrobenzaldehyde , O-[[ (4-butoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above.
  • Analytical HPLC 1.83 min. (85%). Mass Spec: 358.17 (MH+).
    • EXAMPLE 60
  • Figure US20050131032A1-20050616-C00125
  • 2-Propanone, O-[[(4-butoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.39 (br. s, 1H), 7.36 (d, 2H, J=8.1 Hz), 6.90 (dd, 2H, J=7.0, 2.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.97 (s, 6H), 1.67 (m, 2H), 1.42 (m, 2H), 0.91 (t, 3H, J=7.0 Hz). Analytical HPLC 1.59 min. (95%). Mass Spec: 265.16 (MH+).
    • EXAMPLE 61
  • Figure US20050131032A1-20050616-C00126
  • 2-Propanone, O-[[(4-butoxyphenylmethyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.44 min. (95%). Mass Spec: 279.32 (MH+).
    • EXAMPLE 62
  • Figure US20050131032A1-20050616-C00127
  • Benzaldehyde, O-[[(4-butoxyphenylmethyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.66 min. (95%). Mass Spec: 327.31 (MH+).
    • EXAMPLE 63
  • Figure US20050131032A1-20050616-C00128
  • 4-Fluorobenzaldehyde, O-[[(4-butoxyphenylmethyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.66 min. (85%). Mass Spec: 345.28 (MH+).
    • EXAMPLE 64
  • Figure US20050131032A1-20050616-C00129
  • 3-Pyridinecarboxaldehyde, O-[[(4-butoxyphenylmethyl)amino]-carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.55 min. (95%). Mass Spec: 328.29 (MH+).
    • EXAMPLE 65
  • Figure US20050131032A1-20050616-C00130
  • 3-Pyridinecarboxaldehyde, O-[[(3-butoxyphenyl)amino]carbonyl]-oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.39 min. (95%). Mass Spec: 314.28 (MH+).
    • EXAMPLE 66
  • Figure US20050131032A1-20050616-C00131
  • 2-Propanone, O-[[(3-butoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.47 min. (97%). Mass Spec: 265.32 (MH+).
    • EXAMPLE 67
  • Figure US20050131032A1-20050616-C00132
  • Benzaldehyde, O-[[(3-butoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.69 min. (92%). Mass Spec: 313.27 (MH+).
    • EXAMPLE 68
  • Figure US20050131032A1-20050616-C00133
  • 4-Fluorobenzaldehyde, O-[[(3-butoxyphenyl)amino]carbonyl]oxime (Scheme 1, Compound D) Prepared as described for the example above. Analytical HPLC 1.71 min. (92%). Mass Spec: 331.30 (MH+).
    • EXAMPLE 69
  • Figure US20050131032A1-20050616-C00134
  • 3-Pyridinecarboxaldehyde, O-[[([1,1′-biphenyl]-4-yl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method A: filtration of the reaction mixture, and the solid was recrystallized from EtOAc/hexanes, provided the title compound as light yellow solid in 38% yield. 1H NMR (DMSO, 400 MHz) δ 10.06 (s, 1H), 8.96 (d, J=2.0 Hz, 1H), 8.74 (s, 1H), 8.72 (dd, J=1.6 Hz, J=4.8 Hz, 1H), 8.25 (dt, J=1.8 Hz, J=6.2 Hz 1H), 7.68-7.63 (m, 6H), 7.67-7.64 (dd, J=4.8 Hz, J=8.4 Hz, 1H), 7.45 (t, J=7.2 Hz, 2H), 7.34 (t, J=7.2 Hz, 1H); 13C NMR (DMSO, 400 MHz) δ 152.7, 152.0, 151.5, 149.3, 139.5, 137.5, 135.0, 134.6, 128.8, 127.0, 126.5, 126.2, 124.0, 119.5; Mass spec.: 318.0 (MH+); Anal. Calcd. for C19H14N3O2: C=72.14%, H=4.46%, N=13.28%; found: C=72.09%, H=4.68%, N=13.14%.
    • EXAMPLE 70
  • Figure US20050131032A1-20050616-C00135
  • 3-Pyridinecarboxaldehyde, O-[[(4′-ethyl-[1,1′-biphenyl]-4-yl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. 1H NMR (DMSO, 400 MHz) δ 10.03 (s, 1 H), 8.97 (d, J=1.7 Hz, 1 H), 8.74 (s, 1H), 8.72 (dd, J=1.7 Hz, J=4.8 Hz, 1H), 8.25 (dt, J=1.6 Hz, J=8.0 Hz 1H), 7.63 (m, 4H), 7.57-7.54 (m, 3H), 7.28 (d, J=8.3 Hz, 2H), 2.63 (q, J=7.2 Hz, 2H), 1.20 (t, J=7.6 Hz, 3H); 13C NMR (DMSO, 400 MHz)δ 8152.6, 151.9, 151.5, 149.3, 142.6, 137.2, 136.9, 135.0, 134.6, 128.2, 126.7, 126.5, 126.1, 124.0, 119.5, 27.7, 15.5; Mass spec.: 346.1 (MH+); Anal. Calcd. for C21H18N3O2: C=73.24%, H=5.26%, N=12.20; found: C=73.10%, H=5.46%, H=12.25%.
    • EXAMPLE 71
  • Figure US20050131032A1-20050616-C00136
  • 3-Pyridinecarboxaldehyde, O-[[(4-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method A provided the title compound as white need like crystal in 24% yield. 1H NMR (DMSO, 400 MHz) δ 9.94, (s, 1 H), 8.96 (d, J=1.7 Hz, 1H), 8.72 (s, 1H), 8.71 (dd, J=1.8 Hz, J=4.9 Hz, 1H), 8.25 (dt, J=1.9 Hz, J=8.0 Hz, 1H), 7.56-7.53 (m 3H), 7.37 (t, J=7.4 Hz, 2H), 7.11 (t, J=8.4 Hz, 1H), 7.03 (d, J=6.8 Hz, 2H), 6.98 (d, 8.2 Hz, 2H); 13C NMR (DMSO, 400 MHz) δ 157.2, 152.5, 151.9, 151.7, 149.3, 134.6, 133.8, 129.9, 126.5, 124.0, 122.9, 121.1, 119.5, 117.8; Mass spec.: 334.0 (MH+); Anal. Calcd. for C19H14N3O3: C=68.66%, H=4.24%, N=12.64%; found: C=68.50%, H=4.49%, N=12.57%.
    • EXAMPLE 72
  • Figure US20050131032A1-20050616-C00137
  • Benzaldehyde, O-[[([1,1′-biphenyl]-4-yl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method B: after removal of the solvent, the residue was chromatographed by silica gel column packed with EtOAc/hexanes or EtOAc/dichloromethane, to provide the title compound as white solid in 25% yield. 1H NMR (CDCl3, 400 MHz) δ 8.44 (s, 1H), 8.18 (br, 1H), 7.75-7.73 (m 2H), 7.61-7.58 (m, 6H), 7.54-7.42 (m, 5H), 7.34 (tt, J=1.2 Hz, J=7.4 Hz, 1H). Anal. Calcd. for C20H15N2O2.0.198H2O: C=75.32%, H=4.87%, N=8.78%; found: C=75.33%, H=5.16%, N=8.66%.
    • EXAMPLE 73
  • Figure US20050131032A1-20050616-C00138
  • Benzaldehyde, O-[[([1,1′-biphenyl]-4-yl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method B provided the title compound as white solid in 14% yield. 1H NMR (CDCl3, 400 MHz) δ 8.40 (s, 1H), 8.09 (br, 1H), 7.77-7.73 (m 2H), 7.60-7.58 (m, 6H), 7.44 (t, J=7.3 Hz, 2H), 7.34 (tt, J=1.2 Hz, J=7.4 Hz, 1H), 7.18 (t, J=8.56 Hz, 2H); 166.6, 164.0, 1.52.7, 151.7, 140.4, 137.4, 136.1, 130.4, 130.3, 128.8, 127.8, 127.2, 126.9, 126.0, 120.0, 116.6, 116.4.
    • EXAMPLE 74
  • Figure US20050131032A1-20050616-C00139
  • Benzaldehyde, O-[[(4′-ethyl-[1,1′-biphenyl]-4-yl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C: after removal of solvent, the residue was dissolved in methanol and filtrated, the filtrate was purified by preparative HPLC with methanol:H2O (30:70 to about 100:0 v/v, containing 1% TFA) as a mobile phase to provide the title compound as white solid in 11% yield. 1H NMR (DMSO, 500 MHz) δ 9.99 (s, 1H), 8.66 (s, 1H), 7.84 (d, J=8.1 Hz, 2H), 7.66-7.60 (m, 4H), 7.57-7.50 (m, 5H), 7.28 (d, J=88.11 Hz, 2H), 2.63 (q, J=7.5 Hz, 2H), 1.21 (m, 3H); 13C NMR (DMSO, 500 MHz) δ 154.8, 151.7, 142.5, 137.4, 136.9, 131.4, 130.3, 128.9, 128.2, 128.0, 126.7, 126.1, 119.4, 27.7, 15.5; Mass spec.: 345.1 (MH+); Anal. Calcd. for C22H20N2O2: C=76.72%, H=5.85%, N=8.13%; found: C=76.67%, H=5.91%, N=8.02%.
    • EXAMPLE 75
  • Figure US20050131032A1-20050616-C00140
  • 4-Fluorobenzaldehyde, O-[[(4′-ethyl-[1,1′-biphenyl]-4-yl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 10% yield. 1H NMR (CDCl3, 400 MHz) δ 8.40 (s, 1H), 8.06 (s, 1H), 7.76-7.73 (m, 2H), 7.59 (m, 4H), 7.52-7.50 (m, 2H), 7.27 (d, J=8.2 Hz, 2H), 7.18 (t, J=8.6 Hz, 2H), 2.70 (q, J=7.6 Hz, 2H), 1.28 (t, J=7.6 Hz, 3H); 13C NMR (CDCl3, 400 MHz) δ 166.0, 164.0, 152.7, 151.7, 143.4, 137.8, 137.4, 135.8, 130.4, 130.3, 128.3, 127.6, 126.8, 120.0, 116.5, 116.4, 28.5, 15.6; Anal. Calcd. for C22H19FN2O2: C=72.91%, H=5.28%, N=7.73%; found: C=72.51%, H=5.40%,N=7.63%.
    • EXAMPLE 76
  • Figure US20050131032A1-20050616-C00141
  • Benzaldehyde, O-[[(4-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method B provided the title compound as white solid in 28% yield. 1H NMR (CDCl3, 500 MHz) δ 8.35 (s, 1H), 8.03 (br, 1H), 7.66 (d, J=8.5 2H), 7.47-7.39 (m, 5H), 7.28-7.25 (m, 2H), 7.02 (t, J=7.4 Hz, 1 H), 6.98-6.92 (m, 4H); Mass spec.: 333.1 (MH+); Anal. Calcd. for C20H16N2O3: C=72.28%, H=4.85%, N=8.43%; found: C=72.12%, H=4.80%, N=8.39%.
    • EXAMPLE 77
  • Figure US20050131032A1-20050616-C00142
  • 4-Fluorobenzaldehyde, O-[[(4-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method B provided the title compound as white solid in 26% yield. 1H NMR (CDCl3, 400 MHz) δ 8.39 (s, 1H), 7.99 (br, 1H), 7.75-7.71 (m, 2H), 7.48 (m, 2H), 7.33 (m, 2H), 7.19-7.15 (m, 2H), 7.09 (t, J=7.4 Hz, 1H), 7.05-6.98 (m, 4H); Anal. Calcd. for C20H15FN2O3.0.185H2O: C=68.11%, H=4.11%, N=7.94%; found: C=68.11%, H=4.36%, N=7.88%.
    • EXAMPLE 78
  • Figure US20050131032A1-20050616-C00143
  • 3-Pyridinecarboxaldehyde, O-[[[4-(phenylmethoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method A provided the title compound as white solid in 50% yield. 1H NMR (CDCl3, 500 MHz) δ 8.90 (br, 1H), 8.75 (br, 1H), 8.43 (s, 1H), 8.09 (d, J=7.9 Hz, 1H), 7.84 (br, 1H), 7.44-7.31 (m, 8H), 6.98 (d, J=8.9 Hz, 2H), 5.07 (s, 2H); 13C NMR (CDCl3, 500 MHz) δ 155.9, 152.6, 151.8, 151.1, 149.7, 136.9, 134.5, 129.9, 128.6, 128.0, 127.5, 123.9, 121.8, 115.5, 70.3; Mass spec.: 348.1 (MH+); Anal. Calcd. for C20H17N3O3: C=69.15%, H=4.93%, N=12.10%; found: C=68.90%, H=5.05%, N=12.10%.
    • EXAMPLE 79
  • Figure US20050131032A1-20050616-C00144
  • 3-Pyridinecarboxaldehyde, O-[[[4-(2-phenylethoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method A provided the title compound as white solid in 21% yield. 1H NMR (CDCl3, 500 MHz) δ 8.92 (br, 1H), 8.77 (br, 1H), 8.44 (s, 1H), 8.11 (d, J=7.9 Hz, 1H), 7.81 (br, 1H), 7.44 (br, 1H), 7.39 (d, J=8.9 Hz, 2H), 7.34-7.28 (m, 4H), 7.26-7.22 (m,1H), 6.90 (dt, J=3.4 Hz, J=8.9 Hz, 2H), 4.17 (q, J=7.15 Hz, 2H), 3.10 (t, J=7.1 Hz, 3H); 13C NMR (CDCl3, 500 MHz) δ 152.4, 151.8, 151.0, 149.5, 180.0, 136.5, 134.6, 129.0, 128.5, 126.5, 122.0, 115, 69.0, 35.8; Mass spec.: 362.0 (MH+); Anal. Calcd. for C21H19N3O3: C=69.79%, H=5.30%, N=11.63%; found: C=69.42%, H=5.26%, N=11.65%.
    • EXAMPLE 80
  • Figure US20050131032A1-20050616-C00145
  • 3-Pyridinecarboxaldehyde, O-[[[4-(3-phenylpropoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method A provided the title compound as white solid in 26% yield. 1H NMR (CDCl3, 500 MHz) δ 8.94 (br, 1H), 8.79 (br, 1H), 8.44 (s,1H), 8.10 (d, J=7.9 Hz, 1H), 7.82 (br, 1H), 7.45 (br, 1H), 7.40 (d, J=8.9 Hz, 2H), 7.30-7.28 (m, 2H), 722-7.18 (m, 3H), 6.90 (dt, J=3.4 Hz, J=8.9 Hz, 2H), 3.96 (t, J=6.3 Hz, 2H), 2.82 (t, J=7.35 Hz, 2H), 2.11 (m, 2H); 13C NMR (CDCl3, 500 MHz) δ 161.5, 152.0, 150.5, 141.5, 134.5, 129.5, 128.5, 128.4, 125.9, 121.8, 115.1, 67.2, 32.1, 30.8; Mass spec.: 376.1 (MH+); Anal. Calcd. for C22H21N3O3: C=70.38%, H=5.64%, N=11.19%; found: C=69.96%, H=5.59%, N=11.03%.
    • EXAMPLE 81
  • Figure US20050131032A1-20050616-C00146
  • 4-Fluorobenzaldehyde, O-[[[4-(phenylmethoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 10% yield. 1H NMR (CDCl3, 500 MHz) δ 8.31 (s, 1H), 7.86 (br, 1H), 7.65 (dd, J=5.3 Hz, J=8.7 Hz, 2H), 7.37-7.30 (m, 6H), 7.27-7.24 (t, J=7.2 Hz, 1H), 7.09 (t, J=8.6 Hz, 2H), 6.91 (dt, J=3.4 Hz, J=8.9 Hz, 2H), 4.99 (s, 2H); Mass spec.: 365.1 (MH+); Anal. Calcd. for C21H17FN2O3: C=69.22%, H=4.70%, N=7.69%; found: C=69.44%, H=4.84%, N=7.54%.
    • EXAMPLE 82
  • Figure US20050131032A1-20050616-C00147
  • 4-Fluorobenzaldehyde, O-[[[4-(2-phenylethoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 48% yield. 1H NMR (CDCl3, 500 MHz) δ 8.31 (s, 1H), 7.85 (br, 1H), 7.67-7.63 (m, 2H), 7.32 (d, J=8.9 Hz, 2H), 7.27-7.21 (m, 4H), 7.18 (t, J=7.0 Hz, 1H), 6.83 (dt, J=3.4 Hz, J=8.9 Hz, 2H), 4.10 (t, J=7.2 Hz, 2H), 3.03 (t, J=7.1 Hz, 2H); Mass spec.: 379.1 (MH+); Anal. Calcd. for C22H19FN2O3: C=69.83%, H=5.06%, N=7.40%; found: C=69.71%, H=5.05%, N=7.21%.
    • EXAMPLE 83
  • Figure US20050131032A1-20050616-C00148
  • 4-Fluorobenzaldehyde, O-[[[4-(3-phenylpropoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 32% yield. 1H NMR (CDCl3, 500 MHz) δ 8.30 (s, 1H), 7.85 (br, 1H), 7.67-7.63 (m, 2H), 7.33 (d, J=8.9 Hz, 2H), 7.22 (t, J=6.0 Hz, 2H), 7.15-7.01 (m, 5H), 6.82 (dt, J=3.4 Hz, J=8.9 Hz, 2H), 3.88 (t, J=6.3 Hz, 2H), 2.74 (t, J=7.4 Hz, 2H), 2.03 (m, 2H); 13C NMR (CDCl3, 500 MHz) δ 156.2, 152.5, 141.5, 130.3, 130.3, 129.7, 128.5, 128.4, 125.9, 121.8, 116.5, 116.3, 115.0, 67.2, 32.1, 30.8; Mass spec.: 393.0 (MH+); Anal. Calcd. for C23H21FN2O3.0.1 H2O: C=70.07%, H=5.42%, N=7.10%; found: C=70.09%, H=5.46%, N=6.71%.
    • EXAMPLE 84
  • Figure US20050131032A1-20050616-C00149
  • Benzaldehyde, O-[[[4-(phenylmethoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 33% yield. 1H NMR (CDCl3, 500 MHz) δ 8.41 (s, 1H), 8.02 (br, 1H), 7.72-7.70 (m, 2H), 7.54-7.37 (m, 9H), 7.34-7.31 (m, 1H), 6.98 (dt, J=3.4 Hz, J=6.9 Hz, 2H), 5.07 (s, 2H); 13C NMR (CDCl3, 500 MHz) δ 155.7, 153.6, 136.9, 131.9, 130.1, 129.8, 129.1, 128.6, 128.2, 128.0, 127.5, 121.8, 115.4; Mass spec.: 347.0 (MH+); Anal. Calcd. for C21H18N2O3: C=72.82%, H=5.24%, N=8.09%; found: C=72.69%, H=5.28%, N=8.00%.
    • EXAMPLE 85
  • Figure US20050131032A1-20050616-C00150
  • Benzaldehyde, O-[[[4-(2-phenylethoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 23% yield. 1H NMR (CDCl3, 500 MHz) δ 8.41 (s, 1H), 8.01 (br, 1H), 7.72-7.70 (m, 2H), 7.54-7.45 (m, 3H), 7.41 (d, J=8.9 Hz, 2H), 7.34-7.28 (m, 4H), 7.26-7.23 (m, 2H), 6.90 (dt, J=3.3 Hz, J=9.0 Hz, 2H), 4.17 (t, J=7.2 Hz, 2H), 3.10 (t, J=7.1 Hz, 2H); 13C NMR (CDCl3, 500 MHz) δ 153.6, 152.3, 138.2, 136.2, 131.9, 129.9, 129.8, 129.1, 129.0, 128.5, 128.2, 126.5, 121.8, 115.1, 69.0, 35.8; Mass spec.: 361.0 (MH+); Anal. Calcd. for C22H20N2O3: C=73.32%, H=5.59%, N=7.77%; found: C=73.34%, H=5.82%, N=7.73%.
    • EXAMPLE 86
  • Figure US20050131032A1-20050616-C00151
  • Benzaldehyde, o-[[[4-(3-phenylpropoxy)phenyl]amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 25% yield. 1H NMR (CDCl3, 500 MHz) δ 8.41 (s, 1H), 8.02 (br, 1H), 7.72-7.71 (m, 2H), 7.54-7.46 (m, 3H), 7.41 (d, J=8.9 Hz, 2H), 7.30 (t, J=6.85 Hz, 2H), 7.23-7.19 (m, 3H), 6.90 (dt, J=3.4 Hz, J=9.0 Hz, 2H), 3.96 (t, J=6.3 Hz, 2H), 2.82 (t, J=7.4 Hz, 2H), 2.12 (m, 2H); 13C NMR (CDCl3, 500 MHz) δ 156.1, 153,6, 152.4, 141.5, 136.2, 131.9, 129.85, 129.80, 128.5, 128.4, 128.2, 126.0, 121.8, 115.0, 67.2, 32.1, 30.8; Mass spec.: 375.0 (MH+); Anal. Calcd. for C23H22N2O3: C=73.78%, H=5.92%, N=7.48%; found: C=73.82%, H=6.02%, N=7.35%.
    • EXAMPLE 87
  • Figure US20050131032A1-20050616-C00152
  • 3-Pyridinecarboxaldehyde, O-[[(3-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 34% yield. 1H NMR (DMSO, 400 MHz) δ 10.06 (s, 1H), 8.93 (d, J=1.6 Hz, 1H), 8.70 (d, J=1.6 Hz, 1H), 8.69 (s, 1H), 8.21 (dt, J=2.0 Hz, J=8.1 Hz, 1H), 7.54 (dd, J=4.9 Hz, J=7.8 Hz, 1H), 7.40 (t, J=7.4 Hz, 2H), 7.34 (t, J=8.1 Hz, 1H), 7.29-7.26 (m, 2H), 7/16 (t, J=7.4 Hz, 1H), 7.03 (dd, J=1.1 Hz, J=8.7 Hz, 2H), 6.71 (m, 1H); 13C NMR (DMSO, 400 MHz) δ 158.1, 152.6, 151.3, 149.7, 138.1, 134.6, 130.3, 129.8, 123.6, 119.2, 114.7, 114.3, 110.2; Mass spec.: 334.0 (MH+); Anal. Calcd. for C19H14N3O3: C=68.46%, H=4.54%, N=12.61%; found: C=68.42%, H=4.42%, N=12.62%.
    • EXAMPLE 88
  • Figure US20050131032A1-20050616-C00153
  • 4-Fluorobenzaldehyde, O-[[(3-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 34% yield. 1H NMR (CDCl3, 500 MHz) δ 8.36 (s, 1H), 8.00 (br, 1H), 7.12 (m, 2H), 7.37-7.27 (m, 4H), 7.22 (t, J=2.1 Hz, 1H), 7.17-7.10 (m, 3H), 7.04 (dt, J=1.1 Hz, J=7.6 Hz, 2H), 6.78 (dt, J=2.1 Hz, J=7.1 Hz, 1 H); 13C NMR (CDCl3, 500 MHz) δ 165.9, 163.9, 158.0, 156.9, 152.8, 151.6, 138.3, 130.4, 130.3, 130.2, 129.8, 126.0, 125.9, 123.5, 119.1, 116.5, 116.4, 114.6, 114.4, 110.3; Mass spec.: 350.9 (MH+); Anal. Calcd. for C20H15FN2O3: C=68.57%, H=4.32%, N=8.00%; found: C=68.77%, H=4.48%, N=7.76%.
    • EXAMPLE 89
  • Figure US20050131032A1-20050616-C00154
  • 4-Fluorobenzaldehyde, O-[[(2-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid,in 16% yield, mp 141.5-142.0° C. 1H NMR (CDCl3, 500 MHz) δ 8.73 (br, 1 H), 8.32 (dd, J=1.3 Hz, J=8.2 Hz, 1H), 8.30 (s, 1H), 7.55-7.51 (m, 2H), 7.36 (t, J=8.7 Hz, 2H), 7.21 (t, J=7.8 Hz, 1H), 7.12 (t, J=7.4 Hz, 1H), 7.11-7.08 (m, 3H), 7.03 (d, J=8.7 Hz, 2H), 6.98 (d, J=1.4 Hz, J=8.1, 1 H); 13C NMR (CDCl3, 500 MHz) δ 156.8, 152.2, 145.0, 130.2, 130.1, 129.9, 129.4, 124.8, 124.1, 123.5, 119.9, 119.1, 117.4, 116.3, 116.2; Mass spec.: 351.0 (MH+); Anal. Calcd. for C20H15FN2O3.0.41 H2O: C=67.15%, H=4.46%, N=7.83%; found: C=67.13%, H=4.39%, N=7.76%.
    • EXAMPLE 90
  • Figure US20050131032A1-20050616-C00155
  • Benzaldehyde, O-[[(2-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 16% yield, mp 141.5-142.0° C. 1H NMR (CDCl3, 500 MHz) δ 8.73 (br, 1H), 8.32 (dd, J=1.3 Hz, J=8.2 Hz, 1H), 8.30 (s, 1H), 7.55-7.51 (m, 2H), 7.36 (t, J=8.7 Hz, 2H), 7.21 (t, J=7.8 Hz, 1H), 7.12 (t, J=7.4 Hz, 1H), 7.11-7.08 (m, 3H), 7.03 (d, J=8.7 Hz, 2H), 6.98 (d, J=1{circumflex over (R)}4 Hz, J=8.1, 1H); 13C NMR (CDCl3, 500 MHz) δ 156.8, 152.2, 145.0, 130.2, 130.1, 129.9, 129.4, 124.8, 124.1, 123.5, 119.9, 119.1, 117.4, 116.3, 116.2; Mass spec.: 351.0 (MH+); Anal. Calcd. for C20H15FN2O3.0.41 H2O: C=67.15%, H=4.46%, N=7.83%; found: C=67.13%, H=4.39%, N=7.76%.
    • EXAMPLE 91
  • Figure US20050131032A1-20050616-C00156
  • Benzaldehyde, O-[[(3-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as gel-like material in 50% yield. 1H NMR (CDCl3, 500 MHz) δ 8.39 (s, 1H), 8.11 (br, 1H), 7.70 (d, J=5.1 Hz, 2H), 7.53-7.45 (m, 3H), 7.37-7.28 (m, 4H), 7.24-7.23 (m 1H), 7.12 (t, J=7.4 Hz, 1H), 7.04 (m, J=7.7 Hz, 2H), 6.79-6.76 (m, 1H); 13C NMR (CDCl3, 500 MHz) δ 158.0, 156.9, 153.9, 151.7, 138.3, 132.0, 130.2, 129.8, 129.6, 129.1, 128.9, 128.2, 123.5, 119.2, 119.1, 114.6, 114.4, 110.4; Mass spec.: 333.0 (MH+); Anal. Calcd. for C20H16N2O3: C=72.28%, H=4.85%, N=8.43%; found: C=72.10%, H=4.72%, N=8.40%.
    • EXAMPLE 92
  • Figure US20050131032A1-20050616-C00157
  • 3-Pyridinecarboxaldehyde, O-[[(2-phenoxyphenyl)amino]carbonyl]oxime (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 42% yield. 1H NMR (CDCl3, 500 MHz) δ 13.26 (br, 1H), 8.91 (d, J=1.6 Hz, 1H), 8.81 (dd, J=1.4 Hz, J=5.2 Hz, 1H), 8.45 (s, 1 H), 8.38 (br, 1H), 8.29-8.27 (m, 2H), 7.66 (dd, J=5.2 Hz, J=8.0 Hz, 1H), 7.37 (t, J=7.5 Hz, 2H), 7.20 (t, J=7.8 Hz, 1H), 7.15 (t, J=7.4 Hz, 1H), 7.08 (td, J=1.5 Hz, J=8.1 Hz, 1H), 7.04 (d, J=8.0 Hz, 1H), 6.95 (dd, J=1.3 Hz, J=8.1 Hz, 1H); 13C NMR (CDCl3, 500 MHz) δ 16101, 160.7, 156.5, 150.6, 149.2, 147.9, 145.5, 145.3, 138.3, 130.1, 128.8, 128.5, 125.6, 124.7, 124.5, 123.8, 119.8, 118.7, 117.8, 116.7, 114.4; Mass spec.: 334.0 (MH+); Anal. Calcd. for C19H15N3O3.0.185H2O: C=67.78%, H=4.60%, N=12.48%; found: C=67.74%, H=4.46%, N=12.47%.
    • EXAMPLE 93
  • Figure US20050131032A1-20050616-C00158
  • 4-Hexyloxyphenylcarbamic acid, phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.81 min. (99%). Mass Spec: 314 (MH+).
    • EXAMPLE 94
  • Figure US20050131032A1-20050616-C00159
  • 4-Hexyloxyphenylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.80 min. (97%). Mass Spec: 331.39 (MH+).
    • EXAMPLE 95
  • Figure US20050131032A1-20050616-C00160
  • 4-Butoxyphenylcarbamic acid, methyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.40 (br. s, 1H), 7.32 (d, 2H, J=8.0 Hz), 6.83 (dd, 2H, J=7.5, 2.5 Hz), 3.89 (t, 2H, J=6.5 Hz), 1.65 (m, 2H), 1.40 (m, 2H), 0.92 (t, 3H, J=7.5 Hz). Analytical HPLC 1.51 min. (95%). Mass Spec: 224.15 (MH+).
    • EXAMPLE 96
  • Figure US20050131032A1-20050616-C00161
  • 4-Heptyloxyphenylcarbamic acid, phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 2.08 min. (91%). Mass Spec: 328.18 (MH+).
    • EXAMPLE 97
  • Figure US20050131032A1-20050616-C00162
  • 4-Heptyloxyphenylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 2.06 min. (99%). Mass Spec: 346.17 (MH+).
    • EXAMPLE 98
  • Figure US20050131032A1-20050616-C00163
  • 4-Octyloxyphenylcarbamic acid, phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.97 min. (85%). Mass Spec: 342.29 (MH+).
    • EXAMPLE 99
  • Figure US20050131032A1-20050616-C00164
  • 4-Octyloxyphenylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.64 min. (90%). Mass Spec: 360.26 (MH+).
    • EXAMPLE 100
  • Figure US20050131032A1-20050616-C00165
  • 4-Butyloxyphenylcarbamic acid, 4-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.47 (d, 2H, J=7.0 Hz), 7.38 (d, 2H, J=4.0 Hz), 7.25 (d, 2H, J=7.0 Hz), 6.90 (dd, 2H, J=6.0, 2.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.72 (m, 2H), 1.40 (m, 2H), 0.92 (t, 3H, J=7.5 Hz); Analytical HPLC 1.90 min. (95%). Mass Spec: 320 (MH+).
    • EXAMPLE 101
  • Figure US20050131032A1-20050616-C00166
  • 4-Decyloxyphenylcarbamic acid, phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 2.09 min. (97%). Mass Spec: 370.38 (MH+).
    • EXAMPLE 102
  • Figure US20050131032A1-20050616-C00167
  • 4-Decyloxyphenylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 2.07 min. (98%). Mass Spec: 388.43 (MH+).
    • EXAMPLE 103
  • Figure US20050131032A1-20050616-C00168
  • 4-Undecyloxyphenylcarbamic acid, phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 2.33 min. (93%). Mass Spec: 384.26 (MH+).
    • EXAMPLE 104
  • Figure US20050131032A1-20050616-C00169
  • 4-Undecyloxyphenylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 2.31 min. (96%). Mass Spec: 402.25 (MH+).
    • EXAMPLE 105
  • Figure US20050131032A1-20050616-C00170
  • 4-Dodecyloxyphenylcarbamic acid, phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 2.18 min. (85%). Mass Spec: 398.36 (MH+).
    • EXAMPLE 106
  • Figure US20050131032A1-20050616-C00171
  • 4-Dodecyloxyphenylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 2.18 min. (95%). Mass Spec: 416.38 (MH+).
    • EXAMPLE 107
  • Figure US20050131032A1-20050616-C00172
  • 4-Butoxyphenylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.61 min. (97%). Mass Spec: 304.18 (MH+).
    • EXAMPLE 108
  • Figure US20050131032A1-20050616-C00173
  • 4-Butoxyphenylcarbamic acid, 4-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 7.33 (d, 2H, J=8.1 Hz), 7.23 (m, 4H), 6.90 (dd, 2H, J=7.0, 2.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.72 (m, 2H), 1.42 (m, 2H), 0.91 (t, 3H, J=7.0 Hz). Analytical HPLC 1.65 min. (95%). Mass Spec: 304.18 (MH+).
    • EXAMPLE 109
  • Figure US20050131032A1-20050616-C00174
  • 4-Butoxyphenylcarbamic acid, 3,4-difluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.71 min. (97%). Mass Spec: 322 (MH+).
    • EXAMPLE 110
  • Figure US20050131032A1-20050616-C00175
  • 4-Butoxyphenylcarbamic acid, 2-methoxyphenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.57 min. (97%). Mass Spec: 316.18 (MH+).
    • EXAMPLE 111
  • Figure US20050131032A1-20050616-C00176
  • 4-(Butoxyphenylmethyl)carbamic acid, phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.59 min. (95%). Mass Spec: 300.0 (MH+).
    • EXAMPLE 112
  • Figure US20050131032A1-20050616-C00177
  • 4-(Butoxyphenylmethyl)carbamic acid, 2-fluorophenyl ester (Scheme 1 B, Compound D″) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.40 (br. s, 1H), 7.26 (m, 6H), 6.90 (d, 2H, J=8.4 Hz), 4.19 (d, 2H, J=6.0 Hz), 3.92 (t, 2H, J=6.5 Hz), 1.67 (m, 2H), 1.42 (m, 2H), 0.91 (t, 3H, J=7.0 Hz). Analytical HPLC 1.59 min. (95%). Mass Spec: 318 (MH+).
    • EXAMPLE 113
  • Figure US20050131032A1-20050616-C00178
  • 4-(Butoxyphenylmethyl)carbamic acid, 4-methoxyphenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.60 min. (95%). Mass Spec: 330.25 (MH+).
    • EXAMPLE 114
  • Figure US20050131032A1-20050616-C00179
  • 4-(Butoxyphenylmethyl)carbamic acid, 6-quinolinyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.30 min. (95%). Mass Spec: 351.25 (MH+).
    • EXAMPLE 115
  • Figure US20050131032A1-20050616-C00180
  • 4-(Butoxyphenylmethyl)carbamic acid, 1-naphthalenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.77 min. (95%). Mass Spec: 350 (MH+).
    • EXAMPLE 116
  • Figure US20050131032A1-20050616-C00181
  • 4-(Butoxyphenylmethyl)carbamic acid, 2-naphthalenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.80 min. (98%). Mass Spec: 350.26 (MH+).
    • EXAMPLE 117
  • Figure US20050131032A1-20050616-C00182
  • 4-(Butoxyphenylmethyl)carbamic acid, 4-(1-methylethyl)phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.82 min. (95%). Mass Spec: 342 (MH+).
    • EXAMPLE 118
  • Figure US20050131032A1-20050616-C00183
  • 4-(Butoxyphenylmethyl)carbamic acid, 3-(dimethylamino)phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.32 min. (90%). Mass Spec: 343.29 (MH+).
    • EXAMPLE 119
  • Figure US20050131032A1-20050616-C00184
  • 4-(Butoxyphenylmethyl)carbamic acid, 4-(trifluoromethyl)phenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.77 min. (99%). Mass Spec: 368.14 (MH+).
    • EXAMPLE 120
  • Figure US20050131032A1-20050616-C00185
  • 4-(Butoxyphenylmethyl)carbamic acid, 2,4-difluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.66 min. (99%). Mass Spec: 336.14 (MH+).
    • EXAMPLE 121
  • Figure US20050131032A1-20050616-C00186
  • 4-(Butoxyphenylmethyl)carbamic acid, 4-fluorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.61 min. (85%). Mass Spec: 318.15 (MH+).
    • EXAMPLE 122
  • Figure US20050131032A1-20050616-C00187
  • 4-(Butoxyphenylmethyl)carbamic acid, 3-chlorophenyl ester (Scheme 1B, Compound D″) Prepared as described for the example above. Analytical HPLC 1.72 min. (86%). Mass Spec: 334.12 (MH+).
    • EXAMPLE 123
  • Figure US20050131032A1-20050616-C00188
  • 4-Phenoxyphenylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method C provided the title compound as white solid in 11% yield. 1H NMR (CDCl3, 400 MHz) δ 7.43 (br, 1H), 7.41 (br, 1H), 7.35-7.30 (m, 2H), 7.28-7.13 (m, 4H), 7.09 (dt, J=0.9 Hz, J=7.4 Hz, 1H), 7.03-6.97 (m, 5H); (s, 1H), 8.06 (s, 1H), 7.76-7.73 (m, 2H), 7.59 (m, 4H), 7.52-7.50 (m, 2H), 7.27 (d, J=8.2 Hz, 2H), 7.18 (t, J=8.6 Hz, 2H), 2.70 (q, J=7.6 Hz, 2H), 1.28 (t, J=7.6 Hz, 3H); 13C NMR (CDCl3, 400 MHz) δ 153.6, 129.8, 129.7, 127.0, 126.9, 124.4, 124.1, 123.1, 120.5, 119.8, 119.6, 118.6, 118.5, 116.8, 116.7; Anal. Calcd. for C19H14FNO3: C=70.58%, H=4.36%, N=4.33%; found: C=70.54%, H=4.31%, N=4.21%.
    • EXAMPLE 124
  • Figure US20050131032A1-20050616-C00189
  • 4′-Ethyl-[l1,1′-biphenyl]-4-ylcarbamic acid, 2-fluorophenyl ester (Scheme 1B, Compound D′) Prepared as described for the example above. Using work-up method B provided the title compound as white solid in 30% yield. 1H NMR (CDCl3, 400 MHz) δ 7.57-7.55 (m, 2H), 7.52-7.49 (m, 4H), 7.36-7.33 (m, 1H), 7.30-7.27 (m, 2H), 7.25-7.14 (m, 3H), 7.05 (br, 1H), 2.70 (q, J=7.6 Hz, 2H), 1.28 (t, J=7.6 Hz, 3H); Anal. Calcd. for C21H18FNO2: C=75.21%, H=5.41%, N=4.18%; found: C=75.27%, H=5.40%, N=4.25%.
    Figure US20050131032A1-20050616-C00190
  • Scheme 2 Reaction conditions: (i) R1-halide, NaH, DMF, 50° C.; (ii) NaOH, EtOH, room temp.; (iii) (a) N3P(O)(OPh)2, Et3N, toluene at 105° C., (b) B—OH at 80° C.; R, R1 and B are as defined above.
  • The following Intermediates 40 to 41 may be used to synthesize Examples 125 to 135.
    • Intermediate 40
  • Figure US20050131032A1-20050616-C00191
  • 2-(4-Butoxy-phenyl)-butyric acid methyl ester: (Scheme 2, Compound E) The mixture of methyl 4-butoxyphenylacetate (1.20 g, 5.4 mmol) and NaH (60% in mineral oil, 0.50 g, 12.5 mmol) in DMF (25.0 mL) was stirred at 50° C. for 40 min. Bromoethane (2.0 g, 18.3 mmol) was added and the stirring continued at rt for one hour. The reaction mixture was diluted with EtOAc (300 mL), washed with H2O, and then was dried over Na2SO4. After filtration and concentration in vacuo, the residue was purified by flash chromatography (SiO2: EtOAc/Hexanes). This compound was obtained as a yellow oil (0.85 g, 3.4 mmol, 63% yield). 1H NMR (DMSO-d6) δ 7.16 (d, 2H, J=7.0 Hz), 6.87 (d, 2H, J=8.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 3.55 (s, 3H), 3.45 (t, 1H, J=9.0), 1.93 (m, 1H), 1.63 (m, 3H), 1.42 (m, 2H), 0.97 (t, 3H, J=7.2 Hz), 0.79 (t, 3H, J=4.0 Hz).
    • Intermediate 41
  • Figure US20050131032A1-20050616-C00192
  • 2-(4-Butoxy-phenyl)-butyric acid: (Scheme 2, Compound F) To a solution of 2-(4-butoxy-phenyl)-butyric acid methyl ester (2.0 g, 8.0 mmol) in EtOH (30 mL) was added NaOH (10 N, 6 mL, 60 mmol). The resulting mixture was stirred at rt for 3 hours, diluted with H2O (30 mL), acidified to pH˜1.0 using HCl (6N). The precipitates were filtered off by filter paper, washed by H2O and hexanes. This compound was obtained as a white solid. (1.4 g, 5.9 mmol, 74% yield). 1H NMR (DMSO-d6) δ 12.20 (br. s, 1H), 7.16 (d, 2H, J=7.0 Hz), 6.87 (d, 2H, J=8.5 Hz), 3.92 (t, 2H, J=6.5 Hz), 3.31 (t, 2H, J=6.9 Hz), 1.93 (m, 1H), 1.63 (m, 3H), 1.42 (m, 2H), 0.97 (t, 3H, J=7.2 Hz), 0.79 (t, 3H, J=4.0 Hz).
    • EXAMPLE 125
  • Figure US20050131032A1-20050616-C00193
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid quinolin-6-yl ester (Scheme 2, Compound G) To a solution of 2-(4-butoxy-phenyl)-butyric acid (0.050 g, 0.23 mmol) and Et3N (0.053 g, 0.53 mmol) in toluene (2 mL) was added diphenylphosphoryl azide (0.096 g, 0.35 mmol). The resultant mixture was stirred at r.t. for 10 min. and then at 107° C. under N2 for 60 min. After the mixture was cooled to r.t., quinolin-6-ol (0.050 g, 0.34 mmol) was added. The reaction mixture was stirred at r.t. for 10 min. and then at 80° C. for 1 h. The mixture was diluted with EtOAc, washed with H2O. After filtration and concentration in vacuo, the residue was purified by by preparative HPLC (YMC 30×100 mm (5 uM packing), 10% MeOH/90% water/01% TFA as mobile phase A, 90% MeOH/10% water/0.1% TFA as mobile phase B). This compound was obtained as a pale yellow solid (0.040 g, 0.11 mmol, 46% yield): mp 115-118° C.; 1H NMR (DMSO-d6) δ 8.93 (m, 1H), 8.45 (d, 1H, J=9.OHz), 8.40 (d, 1H, J=8.5), 8.02 (d, 1H, J=9.0 Hz), 7.77 (s, 1H), 7.62 (dd, 1H, J=8.5, 4.5 Hz), 7.55 (dd, 1H, J=9.0, 2.5 Hz), 7.25 (d, 2H, J=8.5 Hz), 6.98 (d, 2H, J=8.5 Hz), 4.43 (m, 1H), 3.95 (t, 2H, J=6.5 Hz), 1.75 (m,1H), 1.65 (m, 3H), 1.42 (m, 2H), 0.90 (m, 6H). Mass Spec: 379.33 (MH+).
    • EXAMPLE 126
  • Figure US20050131032A1-20050616-C00194
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid 4-methoxy-phenyl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.73 min. (88%). Mass Spec: 358.25 (MH+).
    • EXAMPLE 127
  • Figure US20050131032A1-20050616-C00195
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid naphthalen-1-yl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.86 min. (98%). Mass Spec: 378.25 (MH+).
    • EXAMPLE 128
  • Figure US20050131032A1-20050616-C00196
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid naphthalen-2-yl ester (Scheme 2, Compound G) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 8.30 (d, 1H, J=9.0 Hz), 7.90 (m, 3H), 7.60 (s, 1H), 7.45 (m, 2H), 7.25 (m, 3H), 6.90 (d, 2H, J=8.5 Hz), 4.43 (m, 1H), 3.95 (t, 2H, J=6.5 Hz), 1.75 (m, 1H), 1.65 (m, 3H), 1.42 (m, 2H), 0.90 (m, 6H). Analytical HPLC 1.87 min. (99%). Mass Spec: 378.12 (MH+).
    • EXAMPLE 129
  • Figure US20050131032A1-20050616-C00197
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid 4-isopropyl-phenyl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.91 min. (96%). Mass Spec: 370.31 (MH+).
    • EXAMPLE 130
  • Figure US20050131032A1-20050616-C00198
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid 3-trifluoromethyl-phenyl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.84 min. (96%). Mass Spec: 396.18 (MH+).
    • EXAMPLE 131
  • Figure US20050131032A1-20050616-C00199
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid 2,4-difluoro-phenyl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.77 min. (89%). Mass Spec: 364.17 (MH+).
    • EXAMPLE 132
  • Figure US20050131032A1-20050616-C00200
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid 4-fluoro-phenyl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.72 min. (89%). Mass Spec: 346.18 (MH+).
    • EXAMPLE 133
  • Figure US20050131032A1-20050616-C00201
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid 4-dimethylamino-phenyl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.53 min. (96%). Mass Spec: 371 (MH+).
    • EXAMPLE 134
  • Figure US20050131032A1-20050616-C00202
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid phenyl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.70 min. (88%). Mass Spec: 328.19 (MH+).
    • EXAMPLE 135
  • Figure US20050131032A1-20050616-C00203
  • [1-(4-Butoxy-phenyl)-propyl]-carbamic acid 2-fluoro-phenyl ester (Scheme 2, Compound G) Prepared as described for the example above. Analytical HPLC 1.70 min. (89%). Mass Spec: 346.18 (MH+).
    Figure US20050131032A1-20050616-C00204
  • Scheme 3 Reaction conditions: (i) W-acid chloride, Et3N, dichloroethane, room temp.; (ii) NaOH, EtOH, room temp.; (iii) (a) N3P(O)(OPh)2, Et3N, toluene at 105° C., (b) B—OH at 80° C.; W is C1-12 alkyl and B is as defined above.
  • The following Intermediates 42 and 43 may be used to synthesize Examples 136 to 140.
    • Intermediate 42
  • Figure US20050131032A1-20050616-C00205
  • 4-Decanoylamino-benzoic acid ethyl ester: (Scheme 3, Compound H) To a solution of 4-amino-benzoic acid ethyl ester (2.0 g, 12.1 mmol) and decanoyl chloride (2.35 g, 13.3 mmol) in methylene chloride (20 mL) was added Et3N (1.34 g, 13.3 mmol). The resultant mixture was stirred at room temperature for one hour and then was diluted with EtOAc, washed by H2O, dried over MgSO4. After filtration and concentration in vacuo, the product was directly used in the next step.
    • Intermediate 43
  • Figure US20050131032A1-20050616-C00206
  • 4-Decanoylamino-benzoic acid: (Scheme 3, Compound I) To a solution of 4-decanoylamino-benzoic acid ethyl ester (2.0 g, 6.6 mmol) in EtOH (30 mL) was added NaOH (10 N, 6 mL, 60 mmol). The resulting mixture was stirred at rt for 3 hours, diluted with H2O (30 mL), acidified to pH˜1.0 using HCl (6N). The precipitates were filtered off by filter paper, washed by H2O and hexanes. This compound was obtained as a white solid. (1.8 g, 6.5 mmol, 98% yield). 1H NMR (DMSO-d6) δ 9.91 (br. s, 1H), 7.76 (d, 2H, J=8.7 Hz), 6.50 (d, 2H, J=8.7 Hz), 2.29 (t, 2H, J=7.5 Hz), 1.57 (m, 2H), 1.25 (m, 12H), 0.85 (t, 3H, J=6.9 Hz). Mass Spec: 278.21 (MH+).
    • EXAMPLE 136
  • Figure US20050131032A1-20050616-C00207
  • Benzaldehyde, O-[[(4-Nonanoylamino-phenyl) amino]carbonyl]oxime (Scheme 3, Compound J) To a solution of 4-decanoylamino-benzoic acid (0.050 g, 0.18 mmol) and Et3N (0.053 g, 0.53 mmol) in toluene (2 mL) was added diphenylphosphoryl azide (0.096 g, 0.35 mmol). The resultant mixture was stirred at r.t. for 10 min. and then at 107° C. under N2 for 60 min. After the mixture was cooled to r.t., benzaldehyde oxime (0.050 g, 0.41 mmol) was added. The reaction mixture was stirred at r.t. for 10 min. and then at 80° C. for 30 min. The mixture was diluted with EtOAc, washed with H2O. After filtration and concentration in vacuo, the residue was purified by preparative HPLC (YMC 30×100 mm (5 uM packing), 10% MeOH/90% water/01% TFA as mobile phase A, 90% MeOH/10%water/ 0.1% TFA as mobile phase B). This compound was obtained as a pale yellow solid (0.038 g, 0.10 mmol, 53% yield): 1H NMR (DMSO-d6) δ 9.78 (d, 2H, J=9.0 Hz), 8.63 (s, 1H), 7.82 (dd, 2H, J=7.7, 2.4 Hz), 7.52 (m, 5H), 7.44 (d, 2H, J=9.0 Hz), 2.27 (t, 2H, J=9.0 Hz), 1.55 (m, 2H), 1.26 (m, 10H), 0.85 (t, 3H, J=6.6 Hz). Mass Spec: 396.22 (MH+).
    • EXAMPLE 137
  • Figure US20050131032A1-20050616-C00208
  • 4-Fluorobenzaldehyde, O-[[(4-Nonanoylamino-phenyl) amino]carbonyl]oxime (Scheme 3, (Compound J) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.78 (d, 2H, J=9.0 Hz), 8.63 (s, 1H), 7.82 (dd, 2H, J=8.7, 5.4 Hz), 7.52 (d, 2H, J=9.0 Hz), 7.32 (m, 4H), 2.27 (t, 2H, J=9.0 Hz), 1.55 (m, 2H), 1.26 (m, 10H), 0.85 (t, 3H, J=6.6 Hz). AnaL Calcd for C23H28FN3O3: C, 66.81; H, 6.82; N, 10.16. Found: C, 67.07, H, 6.82, N, 10.09. Mass Spec: 414.21 (MH+).
    • EXAMPLE 138
  • Figure US20050131032A1-20050616-C00209
  • 3-Trifluoromethylbenzaldehyde, O-[[(4-Nonanoylamino-phenyl) amino]carbonyl]oxime (Scheme 3, Compound J) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.78 (d, 2H, J=9.0 Hz), 8.63 (s, 1H), 8.15 (m, 2H), 7.92 (d, 1H, J=9.0 Hz), 7.80 (t, 1H, J=7.5 Hz), 7.52 (d, 2H, J=9.0 Hz), 7.32 (d, 2H, J=9.0 Hz)2.27 (t, 2H, J=9.0 Hz), 1.55 (m, 2H), 1.26 (m, 10H), 0.85 (t, 3H, J=6.6 Hz). Anal. Calcd for C24H28F3N3O3: C, 62.19; H, 6.08; N, 9.06. Found: C, 62.45, H, 6.12, N, 8.99. Mass Spec: 464.21 (MH+).
    • EXAMPLE 139
  • Figure US20050131032A1-20050616-C00210
  • 2,4-Difluorobenzaldehyde, O-[[(4-Nonanoylamino-phenyl) amino]carbonyl]oxime (Scheme 3, Compound J) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.78 (s, 2H), 8.63 (s, 1H), 8.05 (m, 1H), 7.52 (m, 4H), 7.22 (m,1H), 2.27 (t, 2H, J=9.0 Hz), 1.55 (m, 2H), 1.26 (m,10H), 0.85 (t, 3H, J=6.6 Hz). Mass Spec: 432.20 (MH+).
    • EXAMPLE 140
  • Figure US20050131032A1-20050616-C00211
  • 3,4-Difluorobenzaldehyde, O-[[(4-Nonanoylamino-phenyl) amino]carbonyl]oxime (Scheme 3, Compound J) Prepared as described for the example above. 1H NMR (DMSO-d6) δ 9.78 (d, 2H, J=8.1 Hz), 8.63 (s, 1H), 8.00 (m, 1H), 7.72-7.42 (m, 6H), 2.27 (t, 2H, J=9.0 Hz), 1.55 (m, 2H), 1.26 (m, 10H), 0.85 (t, 3H, J=6.6 Hz). Mass Spec: 432.20 (MH+).
    Figure US20050131032A1-20050616-C00212
  • Scheme 4 Reaction conditions: (i) (a) Et3N, DPPA/toluene, room temp. to 120° C., (b) oxime, room temp. to 85° C.; A is indolyl wherein K is the corresponding indole carboxylic acid, pyridyl wherein K is the corresponding pyridyl carboxylic acid, or benzofuranyl wherein K is the dibenzofurancarboxylic acid.
  • Examples 141 to 145 were made accordingly.
    • EXAMPLE 141
  • Figure US20050131032A1-20050616-C00213
  • 3-Pyridinecarboxaldehyde, O-[[(1H-indol-5-yl)amino]carbonyl]oxime (Scheme 4, Compound L) To a suspension of indole-5-carboxylic acid (commercially available) (1 mmol) in toluene was added triethylamine (4.0 mmol) and diphenylphosphoryl azide (DPPA) (1.2 mmol) subsequently at room temperature under nitrogen atmosphere. The resultant was stirred for 15 minutes at room temperature followed by 90 minutes at reflux. The reaction mixture was cooled down to room temperature followed by the addition of the corresponding oxime, 3-pyridinealdoxime, (1 mmol). The resultant was stirred for 1 hour at room temperature or followed by heating up to 85° C. Using work-up method A: filtration of the reaction mixture, and the solid was recrystallized from EtOAc/hexanes, provided the title compound as a white solid in 57% yield. 1H NMR (DMSO, 500 MHz) δ 10.99 (s, 1H), 9.68 (s, 1H), 8.94 (d, J=1.7 Hz, 1H), 8.68-8.66 (m, 2H), 8.25 (dt, J=7.9 Hz, J=1.8 Hz, 1H), 7.66 (br, 1H), 7.53 (dd, J=4.8 Hz, J=8.0 Hz, 1H), 7.35 (d, J=8.6 Hz, 1H), 7.31 (t, J=2.8 Hz, 1H), 7.16 (dd, J=1.8 Hz, J=8.6 Hz, 1H), 6.40 (s, 1H); Mass spec.: 281.1 (MH+); Anal. Calcd. for C15H12N4O2: C=64.28%, H=4.32%, N=19.99%; found: C=64.09%, H=4.45%, N=19.759%.
    • EXAMPLE 142
  • Figure US20050131032A1-20050616-C00214
  • 4-Fluorobenzaldehyde, O-[[(1H-indol-5-yl)amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using work-up method C: after removal of solvent, the residue was dissolved in methanol and filtrated, the filtrate was purified by preparative HPLC with methanol:H2O (30:70 to about 100:0 v/v, containing 1% TFA) as a mobile phase to provide the title compound as white solid in 19% yield. 1H NMR (DMSO, 500 MHz) δ 11.03 (s, 1H), 9.59 (s, 1H), 8.64 (s, 1H), 7.93 (dd, J=5.6 Hz, J=8.8 Hz, 2H), 7.69 (br, 1H), 7.38-7.32 (m, 3H), 7.20 (dd, J=1.8 Hz, J=8.7 Hz, 1H), 6.39 (t, J=2.0 Hz, 1H); Mass spec.: 298.0 (MH+); Anal. Calcd. for C16H12N3O2F.0.51 H2O: C=62.713%, H=4.28%, N=13.71%; found: C=62.73%, H=4.13%, N=14.02%.
    • EXAMPLE 143
  • Figure US20050131032A1-20050616-C00215
  • Benzaldehyde, O-[[(lH-indol-5-yl)amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using work-up method C provided the title compound as white solid in 20% yield. 1H NMR (CDCl3, 500 MHz) δ 8.43 (s, 1H), 8.19 (br, 1H), 8.15 (br, 1H), 7.82 (br, 1H), 7.74 (d, J=6.8 Hz, 2H), 7.54-7.46 (m, 3H), 7.38 (d, J=8.6 Hz, 1H), 7.29 (dd, J=1.8 Hz, J=8.7 Hz, 1H), 7.24 (t, J=2.7 Hz, 1H), 6.55 (t, J=2.2 Hz, 1H); Mass spec.: 280.0 (MH+); Anal. Calcd. for C16H13N3O2;0.16H2O: C=68.11%, H=4.76%, N=14.89%; found: C=68.15%, H=4.77%, N=14.75%.
    • EXAMPLE 144
  • Figure US20050131032A1-20050616-C00216
  • 4-Fluorobenzaldehyde, O-[[(1H-indol-3-yl)amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using workup method C and then B provided the title compound as light blue solid in 20% yield. 1H NMR (DMSO, 500 MHz) δ 10.91 (s, 1H), 9.59 (s, 1H), 8.66 (s, 1H), 7.93 (t, J=5.7 Hz, 1H), 7.66 (d, J=7.9 Hz, 1H), 7.44 (m, 1H), 7.36 (t, J=8.1 Hz, 2H), 7.25 (m, 1H), 7.10 (t, J=8.1 Hz, 1H), 7.0 (t, J=7.7 Hz, 1H).
    • EXAMPLE 145
  • Figure US20050131032A1-20050616-C00217
  • Benzaldehyde, O-[[(1H-indol-3-yl)amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using work-up method C and then B (after removal of the solvent, the residue was chromatographed by silica gel column packed with EtOAc/hexanes or EtOAc/dichloromethane) provided the title compound as a light blue solid in 11% yield. 1H NMR (CDCl3, 500 MHz) δ 8.45 (s, 1H), 8.15 (br,1H), 8.05 (br, 1H), 7.75 (d, J=6.9 Hz, 2H), 7.62 (d, J=1.5 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.55-7.48 (m, 3H), 7.39 (d, J=8.2 Hz, 1H), 7.25 (t, J=8.0 Hz,1H), 7.18 (t, J=7.9 Hz, 1H); Mass spec.: 280.0 (MH+). Anal. Calcd. for C16H13N3O2.0.21H2O: C=67.89%, H=4.78%, N=14.84%; found: C=67.91%, H=4.94%, N=14.17%.
    • EXAMPLE 146
  • Figure US20050131032A1-20050616-C00218
  • 4-Fluorobenzaldehyde, O-[[[4-[(4-pyridinyl)oxy]phenyl]amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using work-up method B provided the title compound as light blue solid in 29% yield. 1H NMR (CDCl3, 500 MHz) δ 8.47 (d, J=6.0 Hz, 2H), 8.40 (s, 1H), 8.15 (br, 1H), 7.74 (dd, J=8.05 Hz, J=11.55 Hz, 2H) 7.6 (d, J=8.9 Hz, 2H), 7.17 (t, J=8.55 Hz, 2H), 7.11 (d, J=8.9 Hz, 2H), 6.86 (dd, J=1.5 Hz, J=4.8 Hz, 2H); Mass spec.: 352.34 (MH+).
    • EXAMPLE 147
  • Figure US20050131032A1-20050616-C00219
  • 3-Pyridinecarboxaldehyde, O-[[[4-[(2-pyridinyl)oxy]phenyl]amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using work-up method B provided the title compound as white solid in 30% yield. 1H NMR (DMSO, 300 MHz) δ 9.96 (s, 1H), 8.97 (d, J=1.8 Hz, 1H), 8.73 (s, 1H), 8.72 (dd, J=1.8 Hz, J=4.9 Hz, 1H), 8.25 (dt, J=8.0 Hz, J=2.0 Hz, 1H), 8.14 (dd, J=2.1 Hz, J=5.2 Hz, 1H), 7.84 (td, J=1.9 Hz, J=7.1 Hz, 1H), 7.57-7.53 (m, 3H), 7.13-7.09 (m, 3H), 7.01 (d, J=8.4 Hz, 1H); Mass spec.: 335.11 (MH+). Anal. Calcd. for C18H14N4O3: C=64.67%, H=4.22%, N=16.76%; found: C=64.41%, H=4.16%, N=16.50%.
    • EXAMPLE 148
  • Figure US20050131032A1-20050616-C00220
  • 4-Fluorobenzaldehyde, O-[[[4-[(2-pyridinyl)oxy]phenyl]amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using workup method B provided the title compound as white solid in 22% yield. 1H NMR (CDCl3, 500 MHz) δ 8.39 (s, 1H), 8.20 (dd, J=4.9 Hz, J=1.4 Hz, 1H), 8.05 (br, 1H), 7.75-7.68 (m, 3H), 7.55 (d, J=8.85 Hz, 2H), 7.19-7.14 (m, 4H), 7.00 (dd, J=5.1 Hz, J=7.2 Hz, 1H), 6.91 (d, J=8.30 Hz, 1H); 13C NMR (CDCl3, 500 MHz) δ 165.9, 163.9, 163.7, 152.7, 151.9, 150.5, 147.5, 139.7, 133.5, 130.4, 130.3, 126.03, 126.00, 121.9, 121.2, 118.5, 116.5, 116.4, 111.4; Mass spec.: 352.25 (MH+). Anal. Calcd. for C19H14N3O3F.0.36H2O: C=63.78%, H=4.15%, N=11.74%; found: C=63.74%, H=3.79%, N=11.77%.
    • EXAMPLE 149
  • Figure US20050131032A1-20050616-C00221
  • Benzaldehyde, O-[[[4-[(2-pyridinyl)oxy]phenyl]amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using workup method C provided the title compound as white solid in 76% yield. 1H NMR (CDCl3, 500 MHz) δ 8.42 (s, 1H), 8.27 (dd, J=5.05 Hz, J=1.55 Hz, 1H), 8.17 (br, 1H), 7.76 (td, J=8.65 Hz, J=1.95 Hz, 1 H), 7.72 (d, J=7.05 Hz, 2H), 7.58 (d, J=8.85 Hz, 2H), 7.53 (tt, J=7.25 Hz, J=1.35 Hz, 1H), 7.48 (t, J=6.25 Hz, 2H), 7.15 (dt, J=8.85 Hz, J=3.2 Hz, 2H), 7.07 (dd, J=5.6 Hz, J=6.5 Hz, 1H), 6.89 (d, J=8.35 Hz, 1H); 13C NMR (CDCl3, 500 MHz) δ 163.5, 153.9, 152.0, 150.2, 146.7, 140.7, 134.0, 132.0, 129.7, 129.1, 128.2, 121.9, 121.4, 118.7, 111.3; Mass spec.: 334.27 (MH+). Anal. Calcd. for C19H15N3O3.0.185H2O: C=67.78%, H=4.60%, N=12.48%; found: C=67.79%, H=4.29%, N=12.55%.
    • EXAMPLE 150
  • Figure US20050131032A1-20050616-C00222
  • 4-Fluorobenzaldehyde, O-[[[4-[(3-pyridinyl)oxy]phenyl]amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using workup method B provided the title compound as white solid in 93.5% yield. 1H NMR (CDCl3, 500 MHz) δ 8.39 (s, 1H), 8.38 (d, J=12.5 Hz, 2H), 8.08 (br, 1H), 7.75-7.72 (m, 2H), 7.54 (d, J=8.8 Hz, 2H), 7.34-7.29 (m, 2H), 7.19-7.15 t, J=8.45 Hz, 2H), 7.05 (d, J=8.8 Hz, 2H); Mass spec.: 352.09 (MH+). Anal. Calcd. for C19H14FN3O3.1.38H2O: C=60.66%, H=4.49%, N=11.17%; found: C=60.62%, H=4.24%, N=11.30%.
    • EXAMPLE 151
  • Figure US20050131032A1-20050616-C00223
  • Benzaldehyde, O-[[[4-[(3-pyridinyl)oxy]phenyl]amino]carbonyl]oxime (Scheme 4, Compound L) This material was prepared by the general method where R =4-(3-pyridoxy)benzoic acid, R′=benzaldehyde oxime. Using workup method C and then B provided the title compound as white solid in 7% yield.
  • 1H NMR (CDCl3, 500 MHz) δ 8.43 (s, 1H), 8.38 (d, J=20.0 Hz, 2H), 8.17 (br, 1H), 7.12 (d, J=7.0 Hz, 2H), 7.56-7.46 (m, 5H), 7.32 (m, 2H), 7.05 (d, J=6.9 Hz, 2H); Mass spec.: 334.12 (MH+). Anal. Calcd. for C19H15N3O3.0.21H2O: C=67.69%, H=4.61%, N=12.46%; found: C=67.75%, H=4.81%, N=12.22%.
    • EXAMPLE 152
  • Figure US20050131032A1-20050616-C00224
  • 3-Pyridinecarboxaldehyde, O-[[(2-dibenzofuranyl)amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using work-up method A provided the title compound as white solid in 25% yield. 1H NMR (CDCl3, 500 MHz) δ 8.94 (br, 1H), 8.77 (d, J=3.0 Hz, 1H), 8.49 (s, 1H), 8.25 (s, 1H), 8.14 (d, J=6.75 Hz, 1H), 8.09 (br, 1H), 7.97 (d, J=7.6 Hz, 1H), 7.57 (t, J=7.3 Hz, 2H), 7.50-7.46 (m, 3H), 7.36 (t, J=7.8 Hz, 1H); Mass spec.: 332.24 (MH+). Anal. Calcd. for C19H13N3O30.19H2O: C=68.19%, H=4.03%, N=12.56%; found: C=68.18%, H=3.99%, N=12.49.
    • EXAMPLE 153
  • Figure US20050131032A1-20050616-C00225
  • 4-Fluorobenzaldehyde, O-[[(2-dibenzofuranyl)amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using workup method C provided the title compound as white solid in 8% yield. 1H NMR (CDCl3, 500 MHz) δ 8.43 (s, 1H), 8.25 (s, 1H), 8.20 (br, 1H), 7.97 (dd, J=7.7 Hz, J=0.45 Hz, 1H), 7.76 (m, 2H), 7.56 (t, J=9.75 Hz, 2H), 7.48 (t, J=7.3 Hz, 2H), 7.35 (t, J=7.5 Hz, 1H), 7.19 (t, J=8.65 Hz, 2H); 13C NMR (CDCl3, 500 MHz) δ 156.9, 152.7, 152.3, 130.4, 130.3, 127,5, 122.8, 120.9, 116.5, 116.4, 111.9, 111.7; Mass spec.: 349.10 (MH+). Anal. Calcd. for C20H13FN2O3: C=68.96%, H=3.76%, N=8.04%; found: C=68.82%, H=3.77%, N=7.77%.
    • EXAMPLE 154
  • Figure US20050131032A1-20050616-C00226
  • Benzaldehyde, O-[[(2-dibenzofuranyl)amino]carbonyl]oxime (Scheme 4, Compound L) Prepared as described above. Using work-up method C provided the title compound as white solid in 21% yield. 1H NMR (CDCl3, 500 MHz) δ 8.46 (s, 1H), (8.29 (br, 1H), 8.26 (d, J=1.95 Hz, 1H), 7.97 (d, J=7.5 Hz, 1H), 7.75 (dd, J=8.5 Hz, J=1.5 Hz, 2H), 7.58-7.46 (m, 7H), 7.36 (t, J=7.7 Hz, J=1H); 13C NMR (CDCl3, 500 MHz) δ 156.9, 153.8, 153.2, 152.4, 132.1, 132.0, 129.7, 129.1, 128.3, 127.5, 124.9, 124.1, 122.8, 121.0, 120.0, 112.6, 111.9, 111.8; Mass spec.: 331.12 (MH+). Anal. Calcd. for C20H14N2O3.0.135H2O: C=72.19%, H=4.07%, N=8.42%; found: C=72.20%, H=4.07%, N=8.33.
    • EXAMPLE 155
  • Figure US20050131032A1-20050616-C00227
  • (1Z)-N-[[[(4-butoxyphenyl)amino]carbonyl]oxy]ethanimidoyl chloride This compound was synthesized in accordance with the following literature references: Ivanov, Y. et al., Anticholinesterase activity of O-carbamoylated acylhydroxymoyl chlorides, Khim-Farm Zh., 26:5, 62-63, 1992; and Sakamoto, T. et al., A new synthesis of nitriles from N-alkoxyimidoyl halides with zinc, Synthesis, 9: 750-752, 1991.
  • Biological Data:
  • Homogenates of crude membranes were prepared from H4 cells that express transfected human FAAH (H4-FAAH cells). Briefly, cells were grown in DMEM supplemented with 10% FBS and Geneticin at a final concentration of 500 μg/ml(Gibco BRL, Rockville, Md.). Confluent cultures of H4-FAAH cells were rinsed twice with phosphate-buffered saline [138 mM NaCl, 4.1 mM KCl, 5.1 mM Na2PO4, 1.5 mM KH2PO4 (pH 7.5), 37° C.] and incubated for 5 to 10 minutes at 4° C. in lysis buffer [1 mM sodium bicarbonate]. Cells were transferred from plates to polypropylene tubes (16×100 mm), homogenized and centrifuged at 32,000×g for 30 minutes. Pellets were resuspended by homogenization in lysis buffer and centrifuged at 32,000×g for 30 minutes. Pellets were resuspended in lysis buffer (15-20 μg protein/ml) then stored at −80° C. until needed. On the day of an experiment, membranes were diluted to 2.67 μg protein/ml in 125 mM Tris-Cl, pH 9.0.
  • Activity of FAAH was measured using a modification of the method described by Omeir et al., 1995 (Life Sci 56:1999, 1995). Membrane homogenates (240 ng protein) were incubated at room temperature for one hour with 1.67 nM anandamide [ethanolamine 1- 3H] (available from American Radiolabeled Chemical Inc., St Louis, Mo.) and 10 μM anandamide (available from Sigma/RBI, St. Louis, Mo.) in the absence and presence of inhibitors. The reaction was stopped by the addition of 1 volume of a solution of 1:1 methanol and dichloroethane. The mixture was shaken and then centrifuged at 1000×g for 15 minutes to separate the aqueous and organic phases. An aliquot of the aqueous phase, containing [3H]-ethanolamine was withdrawn and counted by scintillation spectroscopy. Data were expressed as the percentage of [3H]-ethanolamine formed versus vehicle, after subtraction of the background radioactivity determined in the presence of 10 μM arachidonyl trifluoromethyl ketone (ATFMK), an inhibitor of FAAH. IC50 values were determined using a four-parameter logistic equation for dose-response curves. Compounds for which IC50 values are not provided herein showed no FAAH inhibition or marginal FAAH inhibition in preliminary tests.
    TABLE I
    Ex. No. IC50 (nM)
    1 ++++
    2 ++++
    3 ++++
    4 ++++
    5 ++++
    6 ++
    7 ++
    8 +++
    9 +++
    10 ++++
    11 ++++
    12 +++
    13 +++
    14 ++++
    15 ++
    16 +++
    17 ++++
    18 +
    19 ++
    20 ++
    21 +
    22 +++
    23 ++++
    24 ++++
    25 ++++
    26 ++++
    27 ++++
    28 ++++
    29 ++++
    30 ++++
    31 ++++
    32 ++++
    33 ++++
    34 ++++
    35 ++++
    36 ++++
    37 ++++
    38 ++++
    39 ++++
    40 ++++
    41 ++++
    42 ++++
    43 ++++
    44 +++
    45 ++++
    46 ++++
    47 ++++
    48 ++++
    49 ++++
    50 ++++
    51 ++++
    52 ++++
    53 ++++
    54 ++++
    55 ++++
    56 ++++
    57 ++++
    58 +
    59 ++++
    60 +++
    61 +
    62 +++
    63 +++
    64 +++
    65 +++
    66 +
    67 +++
    68 +++
    69 +++
    70 +++
    71 ++++
    72 +++
    73 +++
    74 ++++
    75 ++++
    76 ++++
    77 ++++
    78 ++++
    79 ++++
    80 ++++
    81 ++++
    82 ++++
    83 ++++
    84 ++++
    85 ++++
    86 ++++
    87 ++++
    88 ++++
    89 +
    90 +++
    91 ++++
    92 +
    93 +++
    94 +
    95 +
    96 ++++
    97 +++
    98 ++++
    99 +++
    100 +++
    101 ++++
    102 ++++
    103 ++++
    104 +++
    105 ++++
    106 +++
    107 ++
    108 ++
    109 +
    110 +
    111 ++++
    112 ++++
    113 ++++
    114 ++++
    115 +++
    116 +++
    117 +++
    118 +++
    119 +++
    120 ++++
    121 ++++
    122 +++
    123 +
    124 +
    125 +++
    126 +++
    127 ++
    128 +++
    129 ++
    130 +++
    131 +++
    132 +++
    133 +++
    134 +++
    135 ++++
    136 +++
    137 +++
    138 +++
    139 ++++
    140 +++
    141 +
    142 +
    143 +
    144 +
    145 +
    146 ++
    147 ++
    148 +++
    149 +++
    150 ++++
    151 ++++
    152 ++
    153 +++
    154 +++
    155 ++++

    ++++ = <10 nM;

    +++ = ≧10-100 nM;

    ++ = ≧101-500 nM;

    + = >500 nM
  • The following pain models below utilized Example 5. CARRAGEENAN-INDUCED THERMAL HYPERALGESIA (Chronic Inflammatory Pain): Example 5 (40 mg/kg, i.p.) suppressed the development of thermal hyperalgesia induced by paw carrageenan. Paw carrageenan injection (⋄, 0.45 Carr) produced strong thermal hyperalgesia as evidenced by the short escape latencies seen in vehicle treated rats (⋄,2:15 hr, Carr) as compared to the long baseline latencies (0:00 hr). Animals pretreated with Example 5 (#1, 0:15 hr) failed to exhibit hyperalgesic responses (compare ⋄ to ▪ at 2:15 hr) and instead the latencies for drug treated animals were comparable to baseline. By 120 min post-carrageenan (2:45 hr), partial development of hyperalgesia was observed, that was reversed by a second injection of Example 5 (#2, 3:00 hr) which maintained thermal escape responses at basal levels for another hour (3:00-4:00 hr). No side effects were observed at 40 mg/kg, i.p. in drug (▪) or vehicle (⋄) treated controls (CEW=Cremophor:Ethanol:Water 10:10:80, 2 ml/kg). Data are mean +/− s.e.m. (n=8 per group). * p<0.05, ** p<0.01 Tukey's HSD, compared to vehicle. The results are shown in Table II below.
    Figure US20050131032A1-20050616-P00001
  • HARGREAVES TEST (Acute Thermal Pain) Example 5 (10 & 30 mg/kg; 2 ml/kg; i.v. hand infusion) produced a significant reversal of acute thermal pain behavior at 15 min post injection, which did not persist beyond this time. No significant side effects were observed at 10 mg/kg. However, at 30 mg/kg side effects included strong sedation, reduced activity and splayed hindlimbs. Data are mean +/− s.e.m. (n=8 per group). ** p<0.01 Dunnett's Test, compared to vehicle control. The results are shown in Table III below.
    Figure US20050131032A1-20050616-P00002
  • PAW EDEMA MODEL (Inflammation-induced Edema) The effects of Example 5 on carrageenan-induced edema were examined in a quantitative manner (plethysmometry). Injections of carrageenan (2% lambda) into the plantar aspect of both hind paws, resulted in an increase in combined total paw volume (swelling) measured 3 hours post-injection. Example 5 inhibited swelling by 26% at 40 mg/kg (Ex. 5-40, ip administered at −30 min and +2hr relative to carrageenan) but showed no efficacy at 20 mg/kg (Ex. 5-20, ip). The reference agent dexamethasone (Dex, 1 mg/kg, ip) inhibited swelling by 70%. Table IV, below, summarizes the data.
    Figure US20050131032A1-20050616-P00003

Claims (32)

1. A compound of Formula I:
Figure US20050131032A1-20050616-C00228
or a pharmaceutically acceptable salt or solvate thereof,
wherein
A is represented by Formula II:
Figure US20050131032A1-20050616-C00229
wherein
a is 1 or 2;
R is C1-16 alkoxy optionally substituted with phenyl, pyridyl or morpholinyl; phenyl optionally substituted with C1-4 alkyl; phenoxy; phenyl-C1-4 alkyloxy-; pyridyloxy; pyridyl-C1-4 alkyloxy-; —N(H)—C(O)—C1-16 alkyl; or —C(O)—N(H)—C1-16 alkyl;
R1 is a bond or a C1-3 branched or linear aliphatic hydrocarbon; and
B is C1-4alkyl, indolyl, benzofuranyl, benzothienyl, dibenzofuranyl; dibenzothienyl, fluorenyl, carbazolyl, naphthyl, quinolinyl or isoquinolinyl, wherein each is optionally substituted with one or more of the same or different substituent selected from the group consisting of C1-4 branched or linear aliphatic hydrocarbon, C1-4 alkoxy, halo, haloalkyl, nitro and (C1-3 alkyl)0-2amino-; or Formula IV:
Figure US20050131032A1-20050616-C00230
wherein
X is CH or nitrogen;
R4 is C1-4 branched or linear aliphatic hydrocarbon, C1-4 alkoxy, halo, haloalkyl, nitro or amino; and
b is 0 to 3.
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. The compound of claim 1 wherein B is represented by Formula IV:
Figure US20050131032A1-20050616-C00231
wherein
X is CH;
R4 is halo; and
b is 1.
7. The compound of claim 1 wherein B is represented by Formula IV:
Figure US20050131032A1-20050616-C00232
wherein
X is nitrogen; and
b is 0.
8. The compound of claim 1 wherein B is represented by Formula V:
Figure US20050131032A1-20050616-C00233
wherein X is nitrogen.
9. The compound of claim 1 wherein B is represented by Formula IV or Formula V:
Figure US20050131032A1-20050616-C00234
wherein
X is CH or nitrogen,
R4 is C1-4 branched or linear aliphatic hydrocarbon, C1-4 alkoxy, halo, haloalkyl or amino, and
b is 0 to 3.
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. A compound of Formula VII:
Figure US20050131032A1-20050616-C00235
or a pharmaceutically acceptable salt or solvate thereof,
wherein
a is 1;
R is C1-12 alkoxy;
R4 is halo;
X is CH or nitrogen; and
b is 0 to 2,
with the proviso that when X is nitrogen then b is 0.
15. The compound of claim 14 wherein X is CH selected from the group consisting of:
(4-undecyloxy-phenyl)-carbamic acid phenyl ester;
(4-decyloxy-phenyl)-carbamic acid phenyl ester;
(4-dodecyloxy-phenyl)-carbamic acid phenyl ester;
(4-octyloxy-phenyl)-carbamic acid 2-fluoro-phenyl ester;
(4-octyloxy-phenyl)-carbamic acid phenyl ester;
(4-heptyloxy-phenyl)-carbamic acid phenyl ester; and
(4-decyloxy-phenyl)-carbamic acid 2-fluoro-phenyl ester.
16. A compound of Formula VIII
Figure US20050131032A1-20050616-C00236
or a pharmaceutically acceptable salt or solvate thereof,
wherein
a is 1;
R is C1-12 alkoxy;
R1 is a C1-3 branched or linear aliphatic hydrocarbon;
R4 is phenyl, C1-3 alkoxy or halo;
X is CH or nitrogen; and
b is 2.
17. The compound of claim 16 wherein X is CH selected from the group consisting of:
(4-butoxy-benzyl)-carbamic acid 4-fluoro-phenyl ester;
pyridine-3-carbaldehyde, O-[[(4-butoxy-benzyl)am ino]carbonyl]oxime;
(4-butoxy-benzyl)-carbamic acid phenyl ester;
[1-(4-butoxy-phenyl)-propyl]-carbamic acid 2-fluoro-phenyl ester;
(4-butoxy-benzyl)-carbamic acid 2,4-difluoro-phenyl ester;
(4-butoxy-benzyl)-carbamic acid 4-methoxy-phenyl ester;
[1-(4-butoxy-phenyl)-propyl]-carbamic acid 4-fluoro-phenyl ester;
(4-butoxy-benzyl)-carbamic acid 2-fluoro-phenyl ester; and
(4-butoxy-benzyl)-carbamic acid 3-chloro-phenyl ester.
18. A compound of Formula IX:
Figure US20050131032A1-20050616-C00237
or a pharmaceutically acceptable salt or solvate thereof,
wherein
a is 1;
R is C1-12 alkoxy;
R1 is a C1-3 branched or linear aliphatic hydrocarbon; and
X is CH or nitrogen.
19. The compound of claim 18 selected from the group consisting of:
(4-butoxy-benzyl)-carbamic acid quinolin-6-yl ester;
(4-butoxy-benzyl)-carbamic acid naphthalen-2-yl ester;
[1-(4-butoxy-phenyl)-propyl]-carbamic acid quinolin-6-yl ester; and
(4-butoxy-benzyl)-carbamic acid naphthalen-1-yl ester.
20. (canceled)
21. A method of treating neuropathic pain, acute pain, chronic pain, emesis, anxiety, feeding behavior, movement disorders, glaucoma, brain injury, or cardiovascular disease in a mammal comprising administering to the mammal a therapeutically effective amount of a compound as defined in claim 1.
22. (canceled)
23. (canceled)
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable carrier, adjuvant or diluent.
US11/039,516 2002-02-08 2005-01-19 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors Abandoned US20050131032A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/039,516 US20050131032A1 (en) 2002-02-08 2005-01-19 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35530202P 2002-02-08 2002-02-08
US10/357,807 US6949574B2 (en) 2002-02-08 2003-02-04 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
US11/039,516 US20050131032A1 (en) 2002-02-08 2005-01-19 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/357,807 Division US6949574B2 (en) 2002-02-08 2003-02-04 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors

Publications (1)

Publication Number Publication Date
US20050131032A1 true US20050131032A1 (en) 2005-06-16

Family

ID=27734499

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/357,807 Expired - Lifetime US6949574B2 (en) 2002-02-08 2003-02-04 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
US11/039,516 Abandoned US20050131032A1 (en) 2002-02-08 2005-01-19 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/357,807 Expired - Lifetime US6949574B2 (en) 2002-02-08 2003-02-04 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors

Country Status (6)

Country Link
US (2) US6949574B2 (en)
EP (1) EP1472215A4 (en)
JP (1) JP2005516986A (en)
AU (1) AU2003210824A1 (en)
PL (1) PL373970A1 (en)
WO (1) WO2003065989A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208923A1 (en) * 2001-03-29 2004-10-21 Michael Davis Acute pharmacologic augmentation of psyschotherapy with enhancers of learning or conditioning
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
WO2009049238A1 (en) * 2007-10-11 2009-04-16 The Regents Of The University Of California Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase
WO2014093277A1 (en) 2012-12-11 2014-06-19 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2014113689A1 (en) * 2013-01-18 2014-07-24 Research Foundation Of The City University Of New York Method for enhancing amidohydrolase activity of fatty acid amide hydrolase
US9353075B2 (en) 2011-11-22 2016-05-31 The Regents Of The University Of California Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)
US9828338B2 (en) 2013-03-15 2017-11-28 The Regents Of The University Of California Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors
US9908848B2 (en) 2013-03-15 2018-03-06 The Regents Of The University Of California Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors
WO2019112968A1 (en) * 2017-12-05 2019-06-13 Peng Wang Processes to produce elagolix
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
MXPA03008823A (en) 2001-03-27 2004-08-12 Univ California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism.
JP4515911B2 (en) * 2002-10-07 2010-08-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Modulation of anxiety by blocking anandamide hydrolysis
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
FR2850377B1 (en) * 2003-01-23 2009-02-20 Sanofi Synthelabo ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2860514A1 (en) * 2003-10-03 2005-04-08 Sanofi Synthelabo ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2005046580A2 (en) * 2003-10-16 2005-05-26 The Regents Of The University Of California Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
FR2865205B1 (en) 2004-01-16 2006-02-24 Sanofi Synthelabo ARYLOXYALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
FR2866885B1 (en) 2004-02-26 2007-08-31 Sanofi Synthelabo PIPERIDINYLALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
SI2937341T1 (en) 2004-12-30 2017-10-30 Janssen Pharmaceutica N.V. 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
ES2433290T3 (en) 2005-02-17 2013-12-10 Astellas Pharma Inc. Piperazine derivatives for the treatment of urinary incontinence and pain
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-keto-oxazoles as modulators of fatty acid amide hydrolase
US20070155707A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
CA2665804A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
CA2674359A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
KR20090121388A (en) * 2007-03-15 2009-11-25 썬 파마 어드밴스트 리서치 컴패니 리미티드 Novel prodrugs
EP2062578A1 (en) * 2007-11-12 2009-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel use of chemical compounds for the treatment of AIDS
TW201006791A (en) * 2008-05-15 2010-02-16 Sigma Tau Ind Farmaceuti Oxime carbamoyl derivatives as modulators of fatty acid amide hydrolase
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
TWI434842B (en) 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
JPWO2010053120A1 (en) 2008-11-06 2012-04-05 アステラス製薬株式会社 Carbamate compound or salt thereof
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
UA108233C2 (en) 2010-05-03 2015-04-10 Fatty acid amide hydrolysis activity modulators
US9249128B2 (en) 2010-10-28 2016-02-02 The Scripps Research Institute Anti-cancer serine hydrolase inhibitory carbamates
CN105418460B (en) * 2014-08-11 2017-04-12 苏州鹏旭医药科技有限公司 Intermediate of pimavanserin and similar compound thereof, and preparation method thereof, and method for preparing pimavanserin and similar compound thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB841141A (en) * 1955-08-29 1960-07-13 Union Carbide Corp Naphthyl esters of n-alkyl-substituted carbamic acids and insecticidal compositions containing the same
NL302370A (en) * 1962-12-22
DE1232947B (en) * 1963-12-09 1967-01-26 Fahlberg List Chemische Veb Process for the preparation of ketoxime carbanilates from ketoximes and aryl isocyanates
AU619038B2 (en) * 1988-08-24 1992-01-16 Teijin Limited Oxime derivatives and herbicides containing the same as an active ingredient
GB9719530D0 (en) * 1997-09-12 1997-11-19 Smithkline Beecham Plc Novel compounds
IL158300A0 (en) * 2001-04-27 2004-05-12 Bristol Myers Squibb Co Bisarylimidazol derivatives and pharmaceutical compositions containing the same

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750030B2 (en) 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20040208923A1 (en) * 2001-03-29 2004-10-21 Michael Davis Acute pharmacologic augmentation of psyschotherapy with enhancers of learning or conditioning
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US9321743B2 (en) 2007-10-11 2016-04-26 The Regents Of The University Of California Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase
US20100311711A1 (en) * 2007-10-11 2010-12-09 The Regents Of The University Of California Inhibitors of NAAA and Methods Thereof
JP2011500602A (en) * 2007-10-11 2011-01-06 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Compositions and methods for inhibiting N-acylethanolamine-hydrolyzed acid amidase
US10363237B2 (en) 2007-10-11 2019-07-30 The Regents Of The University Of California Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase
WO2009049238A1 (en) * 2007-10-11 2009-04-16 The Regents Of The University Of California Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase
US9353075B2 (en) 2011-11-22 2016-05-31 The Regents Of The University Of California Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)
WO2014093277A1 (en) 2012-12-11 2014-06-19 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
US9474271B2 (en) 2013-01-18 2016-10-25 Research Foundation Of The City University Of New York Method for enhancing amidohydrolase activity of fatty acid amide hydrolase
US9849101B2 (en) 2013-01-18 2017-12-26 Research Foundation Of The City University Of New York Method for enhancing amidohydrolase activity of fatty acid amide hydrolase
WO2014113689A1 (en) * 2013-01-18 2014-07-24 Research Foundation Of The City University Of New York Method for enhancing amidohydrolase activity of fatty acid amide hydrolase
US9828338B2 (en) 2013-03-15 2017-11-28 The Regents Of The University Of California Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors
US9908848B2 (en) 2013-03-15 2018-03-06 The Regents Of The University Of California Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors
WO2019112968A1 (en) * 2017-12-05 2019-06-13 Peng Wang Processes to produce elagolix
TWI693208B (en) * 2017-12-05 2020-05-11 大陸商蘇州鵬旭醫藥科技有限公司 Processes to produce elagolix
US11377426B2 (en) 2017-12-05 2022-07-05 Suzhou Pengxu Pharmatech Co., Ltd. Processes to produce elagolix
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake

Also Published As

Publication number Publication date
US20030195226A1 (en) 2003-10-16
JP2005516986A (en) 2005-06-09
WO2003065989A2 (en) 2003-08-14
PL373970A1 (en) 2005-09-19
EP1472215A2 (en) 2004-11-03
AU2003210824A8 (en) 2003-09-02
WO2003065989A3 (en) 2004-02-19
AU2003210824A1 (en) 2003-09-02
US6949574B2 (en) 2005-09-27
EP1472215A4 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
US6949574B2 (en) (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
AU692788B2 (en) Piperazine compounds used in therapy
US5574159A (en) Opioid compounds and methods for making therefor
US5681830A (en) Opioid compounds
US11858900B2 (en) Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
US20100016274A1 (en) Beta-lactam cannabinoid receptor modulators
US20100099682A1 (en) Acetylene derivatives
CA2199621A1 (en) Substituted aryl piperazines as neurokinin antagonists
JP2001502712A (en) Bound somatostatin agonists and antagonists
US20170007614A1 (en) Autotaxin inhibitors
JP2006503875A (en) Quinazolinone derivatives useful as antihyperalgesic agents
US7034031B2 (en) Modulators of TNF-α signaling
US20110250135A1 (en) Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use
US20090163549A1 (en) Pharmaceutical Composition Comprising an Amide Derivative
US20230271955A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN106660968A (en) Pyrazole derivatives and their use as cannabinoid receptor mediators
US9861613B2 (en) GPR142 agonist compounds
JP4550353B2 (en) Hematopoietic prostaglandin D2 synthase inhibitor
US20250289810A1 (en) Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments
RU2667486C2 (en) Alkynyl indazole derivative and use thereof
CN104039151A (en) Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
US20190127320A1 (en) Kcnq2-5 channel activator
JPH09328469A (en) New substituted acetamide compound
JP2004529089A (en) Use of a GAL3 receptor antagonist to treat depression and / or anxiety and compounds useful in such methods
US12358869B2 (en) Diarylureas as CB1 allosteric modulators

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION